===============================================================================

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

-----------------------------

FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report:

(Date of earliest event reported)

MARCH 7, 2007

----------------------------

CNS RESPONSE, INC.
(Exact name of registrant as specified in charter)

DELAWARE
(State or other Jurisdiction of Incorporation or Organization)

0-26285 87-0419387
(Commission File Number) (IRS Employer Identification No.)

2755 BRISTOL ST.
COSTA MESA, CA 92626
(Address of Principal Executive
Offices and zip code)

(949) 248-5461
(Registrant's telephone
number, including area code)

STRATIVATION, INC.
10900 WILSHIRE BLVD., SUITE 500
LOS ANGELES, CA 90024-6525
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of registrant under any of the
following provisions:

[_] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)

[_] Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act
(17 CFR 240.14a-12(b))

[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))

[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))

================================================================================

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Information included in this Form 8-K may contain forward-looking
statements within the meaning of Section 27A of the Securities Act and Section
21E of the Securities Exchange Act of 1934, as amended (the "EXCHANGE ACT").
This information may involve known and unknown risks, uncertainties and other
factors which may cause our actual results, performance or achievements to be
materially different from future results, performance or achievements expressed
or implied by any forward-looking statements. Forward-looking statements, which
involve assumptions and describe our future plans, strategies and expectations,
are generally identifiable by use of the words "may," "will," "should,"
"expect," "anticipate," "estimate," "believe," "intend" or "project" or the
negative of these words or other variations on these words or comparable
terminology. Forward-looking statements are based on assumptions that may be
incorrect, and there can be no assurance that any projections or other
expectations included in any forward-looking statements will come to pass. Our
actual results could differ materially from those expressed or implied by the
forward-looking statements as a result of various factors. Except as required by
applicable laws, we undertake no obligation to update publicly any
forward-looking statements for any reason, even if new information becomes
available or other events occur in the future.

ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.

Reference is made to the description of the Subscription Agreement,
Registration Rights Agreements, and Indemnification Agreement under Item 2.01 of
this report, which description is incorporated by reference into this Item 1.01.

ITEM 2.01 COMPLETION OF ACQUISITION OR DISPOSITION OF ASSETS.

Founded in 2000, and located in Costa Mesa, California, the business of
CNS Response, Inc., a California corporation ("CNSR California"), is focused on
the commercialization of a patented system that aids physicians in the
identification and determination of appropriate and effective medications for
patients with certain behavioral (mental or addictive) disorders. CNSR
California's technology provides medical professionals with medication
sensitivity data for a subject patient based upon the identification and
correlation of treatment outcome information from other patients with similar
neurophysiologic characteristics which are contained in a proprietary outcomes
database. This methodology, called "Referenced-EEG" or "rEEG" represents an
innovative approach to identifying effective medications for patients suffering
from debilitating behavioral disorders. Referenced-EEG and rEEG are registered
trademarks of CNSR California.

In addition, rEEG provides CNSR California with significant
opportunities in the area of pharmaceutical development. Using the rEEG
methodology in combination with CNSR California's proprietary outcomes database,
management believes that CNSR California has the potential to identify new uses
for existing drugs and drug combinations. CNSR California intends to enter into
relationships with established drug and biotechnology companies to further
explore these opportunities.

On January 16, 2007, we entered into an Agreement and Plan of Merger
(the "Merger Agreement") with CNSR California, and CNS Merger Corporation, a
California corporation and our wholly-owned subsidiary ("MergerCo") pursuant to
which we agreed to acquire CNSR California in a merger transaction wherein
MergerCo would merge with and into CNSR California, with CNSR

California being the surviving corporation (the "Merger"). On March 7, 2007, the
Merger closed, CNSR California became our wholly-owned subsidiary, and on the
same date we changed our corporate name from Strativation, Inc. to CNS Response,
Inc.

PRINCIPAL TERMS OF THE MERGER

At the Effective Time of the Merger (as defined in the Merger
Agreement, as amended on February 23, 2007), MergerCo was merged with and into
CNSR California, the separate existence of MergerCo ceased, and CNSR California
continued as the surviving corporation at the subsidiary level. We issued an
aggregate of 17,744,625 shares of our common stock to the stockholders of CNSR
California in exchange for 100% ownership of CNSR California. Additionally, we
assumed an aggregate of 8,407,517 options to purchase shares of common stock and
warrants to purchase shares of common stock on the same terms and conditions as
previously issued by CNSR California.

Immediately prior to the closing of the Merger, we had outstanding
868,823 shares of common stock. Immediately after the closing of the Merger, and
without taking into consideration the Private Placement offering described
below, we had 18,613,448 outstanding shares of common stock, and options and
warrants to purchase 8,407,517 shares of common stock.

PRIVATE PLACEMENT TRANSACTION

On March 7, 2007, simultaneous with the closing of the Merger, we
received gross proceeds of approximately $7,008,450 in a private placement
transaction (the "Private Placement") with institutional investors and other
high net worth individuals ("Investors"). Pursuant to Subscription Agreements
entered into with these Investors, we sold 5,840,374 Investment Units, at $1.20
per Investment Unit. Each "Investment Unit" consists of one share of our common
stock, and a five year non-callable warrant to purchase three-tenths of one
share of our common Stock, at an exercise price of $1.80 per share (the
"Investor Warrant"). We may agree to sell additional Investment Units for a
period of 45 days following March 7, 2007, so that the gross proceeds from the
offering may be in excess of $7,008,450.

We agreed to file a registration statement covering the resale of the
common stock and the common stock underlying the warrants sold in the Private
Placement within 45 days of the closing of the Merger pursuant to the
Subscription Agreement entered into with each Investor.

After commissions and expenses, we received net proceeds of
approximately $6,172,000 in the Private Placement.

Brean Murray Carret & Co. ("Brean Murray") acted as placement agent and
corporate finance advisor in connection with the Private Placement. For their
services as placement agent and financial advisor, pursuant to the terms of an
Engagement Agreement between CNSR California and Brean Murray, Brean Murray
received a retainer in the form of 74,074 shares of our common stock (having a
deemed value of $100,000) upon the closing of the Private Placement. We also
paid Brean Murray a fee equal to 8% of the funds raised in the Private
Placement, or approximately $560,000 of the gross proceeds from the financing.
In addition, Brean Murray received warrants (the "Placement Agent Warrants") to
purchase shares of our common stock in amounts equal to (i) 8% of the shares of
common stock sold by Brean Murray in the Private Placement (467,230 warrants at
an exercise price of $1.45 per share), and (ii) 8% of the shares underlying the
Investor Warrants sold by Brean Murray in the Private Placement (140,169
warrants at an exercise price of $1.80 per share). The Placement Agent Warrants
are fully vested and have a term of 5 years. We also paid $86,000 in costs, fees
and expenses incurred by Brean Murray in connection with the Private Placement.
We expressly assumed CNSR California's agreement with Brean Murray upon the
closing of the Merger. Pursuant to this agreement, Brean Murray has a right of
first

refusal to represent us in certain corporate finance transactions for a period
of one year following the closing of the Private Placement.

REGISTRATION RIGHTS AGREEMENTS

Under the terms of the Subscription Agreements between us and the
Investors in the Private Placement, we are obligated to file a Registration
Statement on Form SB-2 with the Securities and Exchange Commission (the "SEC")
within 45 days following the closing (the "Registration Statement") to permit
the resale of the shares of common stock sold in the Private Placement and
purchasable under the warrants sold in the Private Placement. We will register
the shares on the Registration Statement for resale by those persons who
purchased Investment Units in the Private Placement pro rata based on such
person's percentage interest in the total number of Investment Units sold in the
Private Placement.

The Subscription Agreements also require us to use our reasonable best
efforts to obtain the effectiveness of the Registration Statement not later than
150 days after the closing of the Private Placement, subject to certain
exceptions. After obtaining the effectiveness of the Registration Statement, we
are further obligated to use our reasonable best efforts to maintain the
effectiveness of the Registration Statement until all such shares registered
thereby may be sold without restriction pursuant to Rule 144(k) promulgated
under the Securities Act of 1933, except that investors may not be able to sell
their shares under the Registration Statement during periods when we may be
required to update the information contained in that Registration Statement
under applicable securities laws. If we fail to satisfy our obligations for
obtaining effectiveness of the Registration Statement within 150 days after the
closing of the Private Placement we must pay liquidated cash damages to the
investors in the offering in an aggregate amount equal to 1% of the Investment
Unit purchase price for each share registered, per month that elapses after such
failure until the earlier of (a) the date the Registration Statement is filed or
becomes effective, as applicable, or (b) the date that is one year from the
closing of the Private Placement.

Under the terms of a Registration Rights Agreement entered into between
us and the majority stockholders of our common stock immediately prior to the
Merger, we are also obligated to include up to 767,103 shares of our common
stock on the Registration Statement described above. The registration rights
attaching to the shares held by these stockholders are not transferable with
such shares. Our majority stockholders have identical registration rights to
those provided to the investors, except they do not have the right to liquidated
damages as provided in the Subscription Agreements.

In addition to the registration rights described above, the holders of
the shares (i) sold in the Private Placement, (ii) issuable upon exercise of the
Investor Warrants, (iii) held by the our majority stockholders prior to the
Merger, (iv) issuable upon exercise of the Placement Agent Warrants or otherwise
under the Engagement Agreement with the Placement Agent, and (v) issued upon
conversion of CNSR California Series A Preferred Stock, CNSR California Series B
Preferred Stock and certain shares of CNSR California Common Stock under the
terms of the Merger Agreement, each have piggy-back registration rights with
respect to such shares effective six months following the closing of the Private
Placement, and demand registration rights with respect to such shares effective
one year following the closing of the Private Placement.

Copies of the form of Subscription Agreements and the Registration
Rights Agreements are attached to this report as Exhibits 10.4, 10.6 and 10.7,
respectively, and are incorporated herein by reference.

CNSR CALIFORNIA FUNDINGS PRIOR TO THE MERGER

Since its inception, CNSR California has raised approximately $8.2
million in equity financing. This amount includes the Senior Secured Debt
Financings, Settlement Agreement Financing, Mezzanine Financing, and the Note
Conversion Transaction discussed below.

SENIOR SECURED DEBT FINANCING

From January 2000 through July 2006 CNSR California was primarily
financed through the sale of promissory notes secured by substantially all of
the assets of CNSR California and warrants to purchase CNSR California common
stock pursuant to the terms of Note Warrant and Purchase Agreements between
investors and CNSR California. Through 2006, CNSR California received proceeds
of approximately $3,120,000 from the sale of these notes and warrants. The
aggregate principal amount of the notes sold was approximately $3,117,000.
Substantially all of these notes were converted into CNSR California common
stock in October 2006. See the section below captioned "NOTE CONVERSION
TRANSACTION."

NOTE CONVERSION TRANSACTION

In October 2006, CNSR California and the holders of certain promissory
notes agreed to convert such notes with an aggregate outstanding balance of
$3,061,700 and related accrued and unpaid interest of $1,005,300 at September
30, 2006, into 5,189,294 shares of CNSR California's Series A-1 Preferred Stock,
and 804,221 shares of CNSR California's Series A-2 Preferred Stock. At the
closing of the Merger, the aforementioned shares converted into an aggregate of
5,993,515 shares of our common stock.

SETTLEMENT AGREEMENT FINANCING

In August and September 2006, certain employees and consultants to whom
CNSR California owed an aggregate of $3,199,400 forgave approximately 80% of the
debt and accepted 5,834,117 shares of CNSR California's common stock, and
warrants and options to purchase an aggregate of 270,638 shares of CNSR
California's common stock at $0.59 per share in full settlement of CNSR
California's remaining obligations. At the closing of the Merger, the
aforementioned shares and warrants were converted into 5,834,117 shares of our
common stock and warrants and options to purchase an aggregate of 270,638 shares
of our common stock at $0.59 per share.

MEZZANINE FINANCING

In October 2006, CNSR California sold 1,905,978 units (each, a
"Mezzanine Unit") in a private financing resulting in net proceeds of
$1,925,000. Each Mezzanine Unit consisted of one share of CNSR California's
Series B Preferred Stock and a 5-year warrant to purchase 0.6 shares of CNSR
California's common stock at $1.51 per share. At the closing of the Merger, the
aforementioned shares and warrants were converted into 1,905,978 shares of our
common stock and a warrant to purchase an aggregate of 1,138,835 shares of our
common stock at $1.51 per share on or before October 6, 2011.

TRANSACTIONS SURROUNDING THE MERGER

REVERSE MERGER TRANSACTION FEE

Pursuant to the terms of the Merger Agreement, we paid an advisory fee
of $475,000 to Richardson & Patel, LLP in connection with the Merger upon the
closing of the Private Placement.

CNS RESPONSE, INC. STOCKHOLDER INDEMNIFICATION

Under the terms of the Merger Agreement and an arrangement with our
majority stockholders immediately prior to the Merger, these stockholders have
agreed to indemnify us against certain third party claims made against us
related to our operation from the time they became stockholders through the
consummation of the Merger.

CONVERSION OF NUPHARM DATABASE, LLC PROMISSORY NOTE

In October 2006, CNSR California entered into an agreement with NuPharm
to cancel the Original NuPharm Note in consideration for the extension of the
expiration date of a Warrant to purchase CNSR California Common Stock held by
NuPharm and a new promissory note in the principal amount of $287,423 (the "New
NuPharm Note"). Upon the closing of the Private Placement and Merger, the
principal and accrued interest through December 31, 2006 on the New NuPharm Note
automatically converted into 242,513 shares of our Common Stock.

Immediately upon extension of the of the NuPharm Warrant, NuPharm
exercised the NuPharm Warrant to purchase 2,800,000 shares of CNSR California
common stock for total proceeds of $147,700. At the closing of the Merger, the
aforementioned shares converted into an aggregate of 2,800,000 shares of our
common stock.

RESULT OF THE MERGER AND PRIVATE PLACEMENT TRANSACTIONS

After the completion of the Private Placement and the Merger, we have
an aggregate of 24,692,190 shares of common stock outstanding, with the former
CNSR California shareholders and the investors in the Private Placement owning
in the aggregate 23,584,999 shares of our common stock, which represents
approximately 96.5% of our issued and outstanding shares of common stock. Our
stockholders immediately prior to the Merger and Private Placement owned
approximately 3.5% of our outstanding common stock (or, 868,823 shares of our
common stock) immediately after completion of these transactions.

The issuance of our shares of common stock in the Merger was exempt
from registration under the Securities Act of 1933, as amended (the "Securities
Act"), pursuant to Section 4(2) thereof and an exemption from registration
contained in Regulation D. The issuance of shares of common stock and the
warrants to the Investors in the Private Placement, and the issuance of the
Placement Agent Warrants were completed pursuant to an exemption from
registration contained in Regulation D. The shares of our common stock and
shares of common stock issuable pursuant to the issued warrants may not be
offered or sold in the United States unless they are registered under the
Securities Act, or an exemption from the registration requirements of the
Securities Act is available. No registration statement covering these securities
has yet been filed with the SEC or with any state securities commission in
respect of the Merger or the Private Placement.

On March 9, 2007, we filed a press release announcing the closing and
the completion of the Merger and the Private Placement, a copy of which is
attached to this Current Report on Form 8-K as Exhibit 99.1.

Except for the Merger Agreement, as amended, and the transactions
contemplated by that agreement, neither CNSR California, nor the directors and
officers of CNSR California serving prior to the consummation of the Merger, nor
any of their associates, had any material relationship with us, or any of our
directors and officers, or any of our associates prior to the merger.

We are presently authorized under our Certificate of Incorporation to
issue 750,000,000 shares of common stock, par value $0.001 per share. As of the
closing of the Merger and after the first closing of the Private Placement, we
had 24,692,190 shares of common stock issued and outstanding and 10,767,028
shares of common stock reserved for issuance pursuant to issued and outstanding
options and warrants to purchase shares of our common stock.

NEW OFFICERS AND DIRECTORS

Pursuant to the Merger Agreement our former sole director, Mr. Silas
Phillips, resigned effective as of the closing of the Merger on March 7, 2007,
and the following directors were appointed:

Leonard J. Brandt
David B. Jones
Jerome Vaccaro, M.D.

See ITEM 5.02 "DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF
DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN
OFFICERS."

Also effective as of the closing of the Merger on March 7, 2007, Mr.
Silas Phillips resigned as Chief Executive Officer, Chief Financial Officer and
Secretary and the following officers were appointed by the Board of Directors:

NAME AGE POSITION
- ---- --- --------
Leonard J. Brandt 50 President, Chief Executive Officer and Secretary
Horace Hertz 57 Chief Financial Officer

On January 24, 2007, we filed an Information Statement on Schedule
14f-1 reporting the proposed Merger with CNSR California and the pending change
in the majority of the board of directors at the closing. There are no
arrangements or understandings among members of both the former and new control
groups and their associates with respect to the election of directors or other
matters.

DESCRIPTION OF THE BUSINESS

With respect to this discussion, the terms "we" "us" "our" "CNSR" and
the "Company" refer to CNS Response, Inc., a Delaware corporation and its
wholly-owned subsidiary CNS Response, Inc., a California corporation ("CNSR
California").

GENERAL

Founded in 2000, and located in Costa Mesa, California, our business is
focused on the commercialization of a patented system that aids physicians in
the identification and determination of appropriate and effective medications
for patients with certain behavioral (mental or addictive) disorders. Our
technology provides medical professionals with medication sensitivity data for a
subject patient based upon the identification and correlation of treatment
outcome information from other patients with similar neurophysiologic
characteristics which are contained in a proprietary outcomes database. This
methodology, called "Referenced-EEG" or "rEEG" represents an innovative approach
to identifying effective medications for patients suffering from debilitating
behavioral disorders. Referenced-EEG and rEEG are registered trademarks of CNSR.

Traditionally, prescription of medication for the treatment of
behavioral disorders (such as depression, bipolar disorders, eating disorders,
addiction, anxiety disorders, ADHD and schizophrenia) has been primarily based
on symptomatic factors, while the underlying physiology and pathology of the
disorder is rarely able to be analyzed, often resulting in multiple ineffective,
costly, and often lengthy, courses of treatment before effective medications are
identified. Some patients never find effective medications. We believe that rEEG
offers an improvement upon traditional methods for determining an effective
course of medication because rEEG is designed to correlate the success of
courses of medication and medication combinations, with the neurophysiological
characteristics of a particular patient.

In addition to its utility in providing psychiatrists and other
physicians with medication sensitivity guidance, rEEG provides us with
significant opportunities in the area of pharmaceutical development. rEEG, in
combination with the information contained in the rEEG database, has the
potential to be able to identify novel uses for, and novel combinations of,
neuropsychiatric medications currently on the market and in late stages of
clinical development, as well as aid in the identification of neurophysiologic
characteristics of clinical subjects that may be successfully treated with
neuropsychiatric medications in the clinical testing stage. We intend to enter
into relationships with established drug and biotechnology companies to further
explore these opportunities.

The initial technology, upon which rEEG is based, was originally
developed by an M.D. Pathologist/ Psychiatrist as well as a clinical
Psychiatrist in response to observations within their practice. They partnered
and formalized their activities into NuPharm Database, LLC, for the purpose of
facilitating investment in 1999. At the time of its formation, these founding
physicians assigned all of their rights in the technology to NuPharm.

CNSR California was incorporated in California on January 11, 2000, for
the purpose of acquiring and commercializing the rEEG technology. The patent
application for the primary technology was acquired from Mill City/CNSR, LLC, a
Minnesota limited liability Company in January 2000 pursuant to the terms of a
Contribution and Subscription Agreement which provided for the issuance of
1,000,000 shares of CNSR's common stock to Mill City in exchange for all of its
assets. Mill City had previously acquired all of NuPharm's assets pursuant to an
Asset Purchase Agreement.

THE CHALLENGE AND THE OPPORTUNITY

The "CNS" in CNS Response, Inc. refers to the central nervous system,
the largest part of the nervous system and includes the brain and spinal cord -
organs fundamental to behavioral control. Often referred to as mental illness,
behavioral disorders have accounted for 7.4% of the total increase in health
care spending from 1987-2000, and they are second among the 15 conditions that
contributed the most to rising health care spending over this period (behind
only heart disease at 8.1%).(1)

More than one out of five adolescents, adults or senior adults,
representing more than 60 million people collectively, have mental or addictive
illness, an epidemic by any measure.(2) In any given year, only half of this
population receives some care for their problem.(3) The market for
pharmaceuticals to treat central nervous system disorders in the United States
is measured at more than $44 billion ($68 billion worldwide) or 23% of total
annual pharmaceutical sales.(4) Unfortunately, the vast majority of these
expenditures are not based on blood tests, CT scans, or any objective
measurement of the system being treated. Dr. Steven Hyman, Director of the
National Institute of Mental Health from 1996 to 2002 stated:

"IN MOST BRANCHES OF MEDICINE, PHYSICIANS CAN BASE THEIR DIAGNOSIS ON
OBJECTIVE TESTS: A DOCTOR CAN EXAMINE X-RAYS TO SEE IF A BONE IS
BROKEN, FOR EXAMPLE, OR CAN EXTRACT TISSUE SAMPLES TO SEARCH FOR CANCER
CELLS. BUT FOR SOME COMMON AND SERIOUS PSYCHIATRIC DISORDERS, DIAGNOSES
ARE STILL BASED ENTIRELY ON THE PATIENT'S OWN REPORT OF SYMPTOMS AND
THE DOCTOR'S OBSERVATIONS OF THE PATIENT'S BEHAVIOR." (5)

Collectively, the industry has been waiting to understand the
physiology of behavioral disorders, with the hope of finding an approach that
utilized objective patient data with prescriptive therapy.

Fueling the increase in spending are patients deemed to be
"Treatment-Resistant," typically defined as failing two or more trials of
standard of care therapies of adequate dose and duration. Treatment costs for
such patients are exceedingly high. For example, those in treatment-resistant
depression reach $10,000 annually for patients treated on an outpatient basis
only, and more than $40,000 annually for those treated on an inpatient basis.(6)
Based on conversations with managed behavioral health care organization (MBHO)
executives, the Company estimates that approximately 10% of patients represent
35-40% of MBHOs' patient costs, with the overwhelming majority deemed
treatment-resistant cases. MBHOs manage an estimated 210 million lives in the
U.S. alone, with 115 million covered by four organizations: Magellan, Value
Options, United Behavioral Health and CIGNA Behavioral Health.(7)

Historically, the practice of psychiatric medicine has been operated
subjectively, with treatment decisions involving powerful neuropsychiatric
medications being prescribed with little or no understanding of the underlying
physiology of each patient.(8) Modern medicine has been successful in
establishing etiology and finding effective therapy for only a relatively small
group of mental abnormalities(9) and has, therefore, necessarily had to rely on
symptomatic diagnoses to make course of

- ----------
(1) Moran, Mark, MANY MORE PEOPLE SEEKING MH TREATMENT SINCE 1980S. Psychiatric
News 39-19 at 15 (October 1, 2004).

(2) See SUPRA note 4 at xii.

(3) Id. at viii.

(4) See SUPRA note 2.

(5) Hyman, Steven. E., DIAGNOSING DISORDERS:PSYCHIATRIC ILLNESSES ARE OFTEN
HARD TO RECOGNIZE, BUT GENETIC TESTING AND NEUROIMAGING COULD SOMEDAY BE
USED TO IMPROVE DETECTION, Scientific American, (3): 96-103 (September
2003).

(6) Crown, W.H., Finkelstein, S., Berndt, E.R., Ling, D., Poret, A.W., Rush,
A.J., and Russell, J.M.. THE IMPACT OF TREATMENT-RESISTANT DEPRESSION ON
HEALTH CARE UTILIZATION AND COSTS, 63(11):963-71 (November 2002).

(7) Open Minds Yearbook of Managed Behavioral Health Market Share in the United
States, 1998-1999, at 10-12 (Gettysburg, PA. 1999).

(8) Gardner, R., SOCIOPHYSIOLOGY AS THE BASIC SCIENCE OF PSYCHIATRY, Journal
Theoretical Medicine and Bioethics, 18-4 at 335-356 (December, 1997).

(9) Breggin, P., R., M.D., Toxic Psychiatry: Why Therapy, Empathy and Love Must
Replace the Drugs, Electroshock, and Biochemical Theories of the "New
Psychiatry", at 291 (St. Martin's Press, 1991).

treatment decisions. The prevalence of the prescription of multiple courses of
ineffective medications for patients suffering from mental disorders, coupled
with the attendant economic inefficiencies of the practice of Psychiatry in this
manner demands a logical alternative.

Behavioral disorders are common in the United States and
internationally. An estimated 26.2 percent of Americans ages 18 and older --
about one in four adults -- suffer from a diagnosable mental disorder in a given
year.(10) The market for pharmaceuticals to treat central nervous system
disorders is more than $42 billion in the United States and is the largest
market segment of pharmaceutical sales, surpassing pharmaceuticals to treat
cardiac disease, cancer and diabetes.(11) Traditionally, prescription of
medication for the treatment of these disorders has been based on symptoms,
while the underlying physiology and pathology of the disease has rarely been
addressed. This can result in multiple ineffective, costly and often lengthy
courses of treatment before effective medications are identified, if at all.

OUR SOLUTION

rEEG is a historical outcomes-based information treatment tool
personalized to the functional imbalance of a patient's brain. We believe rEEG
to be the first broad-based objective, quantitative, neurophysiologic biomarker
system for facilitating appropriate and effective treatment for patients
suffering from behavioral (mental or addictive) disorders. In the past year,
psychiatrists in twelve states have used this system to guide treatment of their
treatment-resistant patients.

With a rEEG report, a physician (a "Client-Physician") can obtain
neuropsychiatric medication sensitivity and resistance data for individuals that
have brain abnormalities (abnormalities of electrical power distribution in the
brain) similar to that of their patient. The compelling clinical results and
economics demonstrated in multiple studies completed by either CNSR or
independent parties provide the basis from which, we believe, rEEG will become a
standard for guidance of psychiatric treatment of treatment-resistant patients.
See Section captioned "OUR BUSINESS - REEG CLINICAL TRIALS" for a review of
existing clinical data.

Over the course of the last twenty years the Company and its scientific
founders have collected treatment outcomes for patients using various
medications where the patients' brain function was first measured with an EEG.
CNSR has correlated the EEG features with courses of treatment and outcomes
information provided by Client-Physicians. This information has been
subsequently assembled and organized into a proprietary database that we refer
to as the "rEEG Outcomes Database". As of November 8, 2006, the rEEG Outcomes
Database contained outcomes for over 2000 patients and more than 13,000
treatment trials of medications on these patients.

Using the rEEG analysis method and the information contained in the
rEEG Outcomes Database, CNSR can provide a report (an "rEEG Analytical Report")
to a Client-Physician identifying medication groups (such as antidepressants,
stimulants, anticonvulsants and beta blockers), medication subgroups such as
antidepressant subgroups of SSRI's (selective serotonin reuptake inhibitors, an
example of which is Prozac), TCA's (tricyclic antidepressants, an example of
which is Desipramine), SNRI's (serotonin-norepinephrine reuptake inhibitors, an
example of which is Cymbalta). Further, and most importantly, CNSR's statistical
models in combination with the rEEG Outcomes Database indicates which specific
medications within these subgroups (such as Zoloft, Prozac, Elavil, Wellbutrin,
Effexor) are the most effective for patients whose EEGs evidence similar
characteristics to that of the subject patient.

- ----------
(10) National Institute of Mental Health, The Numbers Count: Mental Disorders In
America (2006), http://www.nimh.nih.gov/publicat/numbers.cfm#Intro.

(11) IMS Health (NYSE: RX), IMS Retail Drug Monitor April 2006,
http://www.imshealth.com/vgn/images/portal/cit_40000873/56/43/78335031IMS%
20Retail%20Drug%20Monitor%20April2006.pdf.

Psychiatric treatment guided by rEEG has been shown, in independent
studies, to be significantly more efficacious than previous treatment practices.
See Section captioned "OUR BUSINESS - REEG CLINICAL TRIALS." Physicians that
have utilized such reports to inform their treatment strategies identify such
reports as 'essential' or 'significantly helpful' in approximately 75% of
patients treated based upon the information contained in the rEEG Analytical
Report. The vast majority of subject patients for whom we have created rEEG
Analytical Reports have been identified by their physicians as
"treatment-resistant," generally understood to be the most challenging,
high-risk and expensive category of patients to treat.(12) Typically, less than
25% of such patients find success in their next treatment efforts.(13)
Management believes that rEEG provides Client-Physicians with a unique tool that
can dramatically improve treatment outcome based on a patient's own
neurophysiology.

REEG METHOD

CNSR's rEEG method consists of the following four integrated components:

Quantitative Quantitative EEG / Medication
Digital EEG + Normative + rEEG Outcomes + Correlations
Analysis Analysis

1. Digital Electrocephalogram ("EEG")

The first step in the rEEG process is a standard digital EEG recording.
An EEG is a non-invasive, painless procedure where a cap of twenty
electrodes records the electrical output of the brain while the patient
is awake, but resting with their eyes closed. The recording normally
takes between 20 and 45 minutes. An EEG is a common, standardized
procedure in neurology, often used in diagnosis of epilepsy or other
neurological disorders such as brain tumor, stroke, encephalopathy etc.

2. Quantitative Normative Analysis

The electrical output at each of the twenty leads is "Fast Fourier"
transformed (a mathematical technique useful in wave analysis) into a
spectrum of electrical power output at various frequency ranges. One
standard approach transforms these waves into defined frequency ranges,
or bands, labeled Delta, Theta, Alpha and Beta. Output of these four
levels of frequency can be compared among the twenty leads. Standard
comparisons include electrical power of each of these bands on an
absolute and relative power basis (% of the total power output). Also,
comparison of various leads can be made for symmetry and coherence (a
measure of the phase of the energy output). Each of these measurements
(or groups of measurements) in a patient can be compared to values for
asymptomatic people (norms) of the same age and noted when they are
outside of standard normal ranges.

Analysis of the rEEG outcomes database has shown that certain abnormal
indications identifiable in an EEG (individually or in combination) are
indicators of probable response to different medication classes and
individual medications. We refer to these as "biomarkers". We have

- ----------
(12) Dewan, M.J., and Pies, R.W., The Difficult-to-Treat Psychiatric Patient, at
37, American Psychiatric Publishing, Inc. (September 2002).

(13) Rush, A.J., Trivedi, M.H., Wisniewski, S.R., Nierenberg, A.A., Stewart,
J.W., Wadren, D., Niederehe, G., Thase, M.E., Labori, P.W., Lebowitz, B.D.,
McGrath, P.J., Rosenbaum, J.F., Sackheim, H.A., Kupfer, D.J., Luther, J.,
and Fava, M., ACUTE AND LONGER-TERM OUTCOMES IN DEPRESSED OUTPATIENTS
REQUIRING ONE OR SEVERAL TREATMENT STEPS: A STAR*D REPORT. Am. J.
Psychiatry; 163: 11, 1905-1917.

identified a significant group of biomarkers that have shown relevance
and we calculate their value for each patient. We then examine the
history of treatment response to specific medications for patients with
similar patterns of abnormality in these biomarkers and compute a
projected sensitivity analysis for the current patient using any of the
specific medications or medication classes where we have sufficient
statistical power.

3. Quantitative rEEG Outcomes Analysis

A core element of rEEG is the rEEG Outcomes Database. This proprietary
database consists primarily of patient digital EEGs, medication
histories and outcomes collected over a 20 year period. An "outcome"
can be defined as a specific measure of change in behavior obtained
while taking specific medications. The rEEG Outcomes Database allows
for statistical correlation of more than 1,100 individual QEEG measures
against medication success, and includes more than 13,000 treatment
episodes with outcomes.

4. EEG / Medication Correlations - Computation of Proprietary
Variables and application of Correlation Engine

Currently, the rEEG Outcomes Database allows the Company to analyze
outcomes related to twenty-seven different medications from the classes
of antidepressants, stimulants, anticonvulsants, beta-blockers and food
supplements. The Company is continually growing the database and adding
additional medications as they become statistically relevant. There are
currently seventy-eight medications marketed in the U.S. for
depression, anxiety disorders, bipolar disorder, schizophrenia,
obsessive-compulsive disorder (OCD), attention-deficit hyperactivity
disorder (ADHD), post-traumatic stress disorder (PTSD), panic disorder,
and insomnia. This does not include sixty-one medications now marketed
in the United States for the treatment of Alzheimer's, Parkinson's
Disease, migraines and Epilepsy.(14)

TREATMENT DECISIONS MADE BY LICENSED PROFESSIONALS

We do not currently operate our own healthcare facilities, employ our
own treating physicians or provide medical advice or treatment to patients. The
Client-Physicians that contract for our rEEG Analytical Reports own their own
facilities or professional licenses, and control and are responsible for the
clinical activities provided on their premises. Patients receive medical care in
accordance with orders from their attending physicians. Physicians who contract
for rEEG Analytical Reports are responsible for exercising their independent
medical judgment in determining the specific application of the information
contained in the rEEG Analytical Reports, and the appropriate course of care for
each patient. Following the prescription of any medication, the
Client-Physicians are presumed to administer and provide continuing care
treatment.

PROCESS FLOW

The flow chart below details the process of inception to rEEG
Analytical Report delivery. Currently, upon receipt of the EEG, a rEEG
Analytical Report is generally delivered to the referring physician 3-4 days. We
expect that through efficiency improvements, turnaround will be reduced to next
day.

- ----------
(14) Drug Reference for FDA Approved Psychiatric Drugs,
http://neurotransmitter.net/drug_reference.html.

PATIENT/PHYSICIAN CNS RESPONSE NEUROLOGIST

________________________ _______________________
| EEG Recording in Field |_\| Transfer to CNS |
| | /| (Secure) |______________
|________________________| |_______________________| |
| |
___________V___________ _________ V__________
| Artifacting | | Neurologist Review |
| (remove eye blinks, | | (confirming that |
| muscle twitches, etc.)|/__| Patient is suitable |
| |\ | for rEEG) |
|_______________________| |_____________________|
|
___________V___________
| Quantitative |
| Normative |
| Analysis |
|_______________________|
|
___________V___________
| Computation of |
| Proprietary Variables |
|_______________________|
|
___________V___________
| |
| Correlation Engine |
|_______________________|
|
________________________ ___________V___________
| Receive rEEG Report | | rEEG Report |
| (Utilize for |/_| Generation |
| Treatment) |\ | and Review |
|________________________| |_______________________|

The chart above shows that the first step in the process is collection
of a digital EEG from the patient. This may be done at the physician's office or
off-site at a testing center. Some physicians own their own equipment for
testing while others arrange for technicians to visit their offices for patient
appointments. This data is then typically transferred to a secure Health
Insurance Portability and Accountability Act ("HIPPA") compliant FTP (File
Transfer Protocol) Internet site, although it can also be sent via overnight
delivery service. Another early step in the process is artifacting. This is the
process of selecting segments of the QEEG record for analysis that are free of
electrical distortions caused by muscle movement. Also, early in the process is
a conventional review of the EEG by a neurologist or neurophysiologist. This
serves as a quality control step to review the overall quality of the recording
and determine whether it is acceptable for rEEG processing. Also at this time,
the neurologist/neurophysiologist will author a review of the conventional EEG.
This will appear on CNSR's Type I rEEG Report.

OUR TECHNOLOGY AND INTELLECTUAL PROPERTY

REEG PATENTS

We have two issued U.S. Patents which together provide CNSR with the
right to exclude others from using the rEEG technology. In addition, these
patents cover the analytical methodology utilized by CNSR with any form of
neurophysiology measurement including SPECT (Single Photon Emission Computed
Tomography), fMRI (Functional Magnetic Resonance Imaging), PET (Positron
Emission Tomography), CAT (Computerized Axial Tomography), and MEG
(Magnetoencephalography)). We do not currently have data on the utility of such
alternate measurements, but we believe they may, in the future, prove to be
useful to guide therapy in a manner similar to rEEG. We have also filed patent
applications for our technology in various foreign jurisdictions.

REEG TRADEMARKS

We have filed trademark applications in the United States for the
following marks: "Referenced-EEG" and "rEEG". We will continue to expand our
brand names and our proprietary trademarks worldwide as our operations expand.

REEG OUTCOMES DATABASE

The rEEG Outcomes Database consists of approximately 13,000 clinical
outcomes across 2,000 patients who had psychiatric or addictive problems. The
CNSR Outcomes database is maintained in two parts:

1. The QEEG Database

The QEEG Database includes EEG recordings and neurometric data derived
from analysis of these recordings. This data is collectively known as
the QEEG Data. QEEG or "Quantitative EEG" is a standard measure that
adds modern computer and statistical analyses to traditional EEG
studies.

2. The Clinical Outcomes Database

The Clinical Outcomes Database consists of physician provided
assessments of the clinical outcomes of patients and their associated
medications. The clinical outcomes of patients are generally recorded
using an industry-standard outcome rating scale, such as the Clinical
Global Impression Global Improvement scale ("CGI-I"). The CGI-I
requires a clinician to rate how much the patient's illness has
improved or worsened relative to a baseline state. A patient's illness
is compared to change over time and rated as: very much improved, much
improved, minimally improved, no change, minimally worse, much worse,
or very much worse. In addition, CNSR may utilize specialized scales
applicable to specific disorders, including the Beck Depression
Inventory and Ham-D scales (Hamilton Depression Rating Scale) for
depression and anxiety.

The format of the data is standardized and that standard is enforced at
the time of capture by a software application. Outcome data is input
into the database by the treating physician or in some cases, their
office staff. Each Client-Physician has access to his/her own patient
data through the software tool that captures clinical outcome data.

We consider the rEEG Outcomes Database to be a valuable trade secret
and are diligent about protecting such information. The rEEG Outcomes Database
is stored on a secure server and only a limited number of employees have access
to it. Any individual that is provided with access to the database is required
to enter into a strict confidentiality agreement.

OUR CURRENT OPERATIONS -- LABORATORY INFORMATION SERVICES

We provide rEEG analysis in a relationship analogous to the support
other physicians have from a reference laboratory or radiology center.
Physicians send us the QEEG data, and we return an analytical report for a
standard charge. This revenue model requires minimal training or impact on their
current operation and is one that physicians readily understand. In some cases,
we also provide the actual patient testing for acquisition of the QEEG data.

Our revenues are currently derived primarily from our Laboratory
Information Services business. We currently offer rEEG Analytical Reports
produced by our laboratory based on QEEG data supplied by the physician or an
independent testing service. There are two primary types of analysis available.

TYPE I ANALYSIS

Type I analysis provides medication sensitivity information based on
statistical probability of improved outcomes against
neurophyisiologically similar patients. It is considered the baseline
measurement where the patient is preferably tested in an unmedicated
state, which means the patient abstains from taking neuropsychiatric
medications that cross the blood-brain barrier and act on the brain for
5 half-lives (can vary from 1 day for Ambien to 5 weeks for Prozac).

TYPE II ANALYSIS

Type II analysis provides medication sensitivity information based on
the changes to the patient's neurophysiology presumed to be from the
intervening treatment. It is, therefore, measured while the patient is
medicated.

Laboratory Information Services are either: 1) billed to the
Client-Physician or 2) billed to the Patient directly. Currently, the vast
majority of the rEEG Analytical Reports produced are billed to the
Client-Physician. We bill our Client-Physicians on a monthly basis.

Typically, after a 90 day medication regime guided by the Type I rEEG,
a Type II rEEG will be ordered if the desired outcome has not been achieved.
This follow-up analyzes changes post-medication in the patient's physiology, and
facilitates the preparation of an rEEG Report with data useful for determining
medication dose adjustment, alternative medicine selection or additional
medication augmentation. Because our Type I analysis has shown strong efficacy
in guiding successful medication of subject patient's disorders, we expect that
requests for Type II analysis will remain at their current levels.

OUR CURRENT MARKETS

CURRENT APPLIED DISORDERS

In the last 12 months, physicians in twelve states have used rEEG in
their practice. A series of eight studies involving rEEG have been conducted
over the last several years cumulating 500 patients. See Section captioned
"Clinical Validation." All studies, which involved most major categories of
psychiatric disorders (except for schizophrenia), have shown rEEG to be
demonstrably effective in guiding treatment. To date, these studies have
addressed the efficacy of rEEG with respect to the following behavioral
disorders:

o Attentional disorders (including Attention Deficit Disorder
("ADD")/Attention Deficit Hyperactivity Disorder ("ADHD");

o Anxiety disorders;

o Depressive disorders;

o Bipolar disorders;

o Impulse control disorders;

o Post Traumatic stress disorder;

o Compulsive and obsessive disorders;

o Eating Disorders (including anorexia nervosa and bulimia
nervosa); and

o Addictive Disorders (including drug and alcohol abuse)

PRIVATE PAYERS

Currently, a large majority of our rEEG Analytical Reports are paid for
directly by patients.

Insurance coverage for treatment of behavioral disorders varies
significantly. Many health plans limit coverage for mental health benefits by
imposing co-payments, deductibles or limits on outpatient visits that are more
restrictive than those placed on physical illness. Many times these benefits do
not extend to addiction treatment. Lack of or limitations on insurance coverage
or exhaustion of insurance coverage often result in patients needing to pay
privately for treatment of behavioral disorders.

Another reason patients pay privately is that access to plan
psychiatrists may be limited, requiring patients to seek non-plan psychiatrists
that only accept direct patient payment. Occasionally, a patient receiving care
from a health plan psychiatrist may become disappointed with the amount of time
they are able to spend with that physician. They may prefer to pay privately in
order to obtain more physician time and attention.

Because of the nature of a behavioral disorder, many patients seek out
private pay psychiatrists as a result of a desire for greater anonymity. Some
patients are concerned about filing reimbursement claims with their employer's
health benefit program, especially in cases where they may not want their
employer to know of their affliction (e.g. addiction, Attention Deficit
Disorder, Obsessive-compulsive Disorder, Impulse Control Disorder).

Still other patients are seeking the best quality of care without
concern for reimbursement. Psychiatrists that accept private pay generally are
able to receive a higher hourly rate from private pay patients than most health
plan provide. As a psychiatrist develops a reputation for quality service they
may be able to focus their practice on private pay patients to a greater degree.
It is this reputation for quality service that may attract some of the patients
seeking best quality of care.

For these reasons and more there are a large number of psychiatrists
that accept only patients paying privately for their services. CNSR has
estimated that these psychiatrists treat approximately 40% of the treatment
resistant patients, which comprises 2 million people in any given year or a
potential annual market of $1.2 billion with present pricing.

MANAGED BEHAVIORAL HEALTH ORGANIZATIONS/MANAGED CARE PAYERS

Currently, only a small portion of our rEEG Analytical Reports are paid
for by insurers or managed healthcare companies.

Many insurance/managed health care companies and many self-insuring
employers providing behavioral health benefits seek to manage these services and
expenditures through separate entities (MBHOs) that focus exclusively on
managing the mental health benefit. MBHOs are separate entities such as Magellan
Health Services or ValueOptions, Inc. or subsidiaries of larger healthcare
management organizations such as United Behavioral Health or CIGNA Behavioral
Health.

MBHOs have developed contracted networks of behavioral health
specialists to service the needs of their insured members. Various policies for
patients and providers help to efficiently deliver the behavioral health
benefit. Employers that contract with MBHOs don't necessarily seek the lowest
cost of care. Often, the employer's goals are to minimize absenteeism,
disruption to their processes or time lost as a result of employee disabilities
and prefer to contract with MBHO's that can deliver a better quality of care,
accomplishing these goals. Employers may contract directly with an MBHO or
utilize MBHO's as part of the total health care managed care contract.

Based on our conversations with MBHO managers, we estimate that a small
subset (10%-15%) of those that seek treatment in any year account for a
disproportionately high percentage (30%-45%) of the total medical costs paid out
by MBHOs. These are typically the treatment resistant patients. In addition to
being burdensome on the MBHO's, these patients are also typically more expensive
to their primary health insurer as compared to other patients because of their
higher use of emergency room services, pharmaceuticals (which are often not
managed by the MBHO), and use of medical services associated with physical
ailments.

We estimate over 1 million patients covered by MBHOs in any given year
are candidates for rEEG Report guidance. At present pricing this represents an
annual market opportunity of $600 million.

TOTAL MARKET PERSPECTIVE

A 2004 Harris Interactive Poll stated that "an estimated 59 million
people, or more than one in four U.S. adults, have received some form of mental
health treatment in the past two years. The vast majority of these people -- an
estimated 48 million -- are being treated with prescription medication.
Medications are clearly the dominant form of mental health treatment in America,
the survey found" (as reported in HEALTH DAY NEWS, May 5, 2004). The poll also
estimated another 24 million people needed but were not getting help because
they had given up on treatment or never pursued treatment. We estimate our
market opportunity for our Laboratory Information Services with respect to
central nervous system disorders to be in excess of $1.5 billion.

PRICING

We typically charge $400.00 to physicians for a Type I rEEG Report, our
standard report, which reflects EEG data obtained while a patient is off of
medications. Occasionally, physicians encounter patients that cannot tolerate
the discontinuation of their current medications to have a standard Type I test.
For these patients, we have a special report, Type I(m), which reflects EEG data
obtained while the patient is medicated with a medication that is in the rEEG
Outcomes Database. By estimating the likely EEG effect from the medication, we
can estimate the rEEG parameters of an unmedicated brain and issue a report
based on such estimation. Pricing to the physician for Type I(m) reports are
$800.

Type II testing is for patients that have a baseline Type I test on
record and have been medicated. A Type II rEEG Report compares changes in
neurophysiology from the Type I test data. We currently charge $200.00 for a
Type II rEEG Report.

Because the primary tasks of rEEG analysis are computer automated,
direct costs of processing are relatively low. Currently, CNSR contracts with a
neurophysiologist to supply a conventional review of and commentary on a
patient's EEG test. CNSR also contracts with outside services to select
artifact-free (an eye-blink and the corresponding electrical signal from same is
an example of an artifact) sections of the recording suitable for rEEG analysis.
These services constitute the majority of the direct costs associated with
processing a rEEG Type I analysis. We plan to bring both of these functions
in-house during 2007, thereby reducing our costs per test, and improving our
margins.

CLINICAL VALIDATION

As summarized in a 2005 American Psychiatric Association Poster,
reviewing results of rEEG guided treatment in prospective, retrospective,
comparative studies and independent physician case series, fairly consistent
results were reported. Generally, rEEG guided therapy, when used in conjunction
with other standard clinical information has shown the ability to guide
physicians to successful outcomes in

70% or more of mostly treatment resistant patients. Various studies in the
literature would suggest the current standard of care for treatment success with
treatment resistant patients is less than half that rate, and in some cases only
10-15%.(15)

COMPLETED INDEPENDENT STUDIES AND TRIALS

Veterans Association CIGNA
Blind Prospective Major Treatment-Resistant Davis-Atlanta
ADD/Depression Study Depression Study Field Trial Case Study
100 Patients 13 Patients 56 Patients 15 Patients
- --------------------------- ------------------------ ------------------------ ------------------------
rEEG-Guided Efficacy rEEG-Guided Efficacy rEEG-Guided Efficacy rEEG-Guided Efficacy
>80% 83% 70% 100%

Monte Nido
Eating Disorder Case Hamilton-Newport Hoffmann-Denver L'Abri Dual Diagnosis
Series Beach Case Series Case Series San Diego Case Series
81 Patients 34 Patients 15 Patients 58 Patients
- --------------------------- ------------------------ ------------------------ ------------------------
rEEG-Guided Efficacy rEEG-Guided Efficacy rEEG-Guided Efficacy rEEG-Guided Efficacy
83% 78% 73% 93%

ADD/DEPRESSION STUDY
-----------------------------------------------------------------------
Prospective study with retrospective analysis.
EFFICACY: >80%

Date: 1995. The initial formalized trial consisted of 100 patients of
which 46 were diagnosed with ADD and 54 with depression. Conventional
thought would have anticipated that the ADD patients would have
responded to the stimulants and the depressed patients would have
responded to the antidepressants. In this study, those that failed to
respond to conventional treatment were treated with non-conventional
medications. rEEG correctly identified which patients would respond to
which medications over 80% of the time. This study was published in
Clinical Electroencephalography.(16)

VETERANS ADMINISTRATION BLINDED PROSPECTIVE MAJOR DEPRESSION STUDY
-----------------------------------------------------------------------

Randomized, Prospective, Double-Blind Study

Date: 1997-1999. A pilot prospective study of severe and long-term
Veterans Administration patients diagnosed with major depressive
disorders was conducted under the direction of Dr Art Kling, former
Vice-Chairman of the Department of Psychiatry at UCLA. The trial
consisted of 13 patients, all diagnosed with depression with average
illness duration of 16 years. As measured by all indices used, all
patients but one in the rEEG guided treatment group showed significant
improvement (86%). In the control group, where patients were treated
without the benefit of rEEG, only one of the patients significantly
improved based upon physician-guided medication selection (17%), and as
it turned out, this patient received the class of medication that rEEG
predicted would most benefit the patient need even though this
knowledge was not available to the physicians in the control group.
This study has been submitted for publication.

- ----------
(15) Dunner, D.L., Rush, A.J., Russell, J.M., Burke, M., Woodard, S., Wingard,
P., and Allen, J., PROSPECTIVE, LONG-TERM, MULTICENTER STUDY OF THE
NATURALISTIC OUTCOMES OF PATIENTS WITH TREATMENT-RESISTANT DEPRESSION. J
Clin Psychiatry. 67(5):688-95 (May 2006).

(16) Suffin, S. C. and Emory, W. H., CLINICAL ELECTROENCEPHALOGRAPHY, 26(2),
1995.

TREATMENT-RESISTANT PATIENT FIELD TRIAL - CIGNA CO-SPONSORSHIP
-----------------------------------------------------------------------

A pilot study conducted between 2000 and 2002 with CIGNA Behavioral
Health and its network of Atlanta psychiatrists included 56
treatment-resistant patients. All patients had previously failed at
least two trials of medication treatments. Utilizing rEEG guidance, 69%
of patients were reportedly responsive to identified treatments.

PHYSICIAN CASE SERIES
-----------------------------------------------------------------------

Six physicians in five different clinical settings covering a wide
variety of diagnoses and ages have now reported on treatment results
aided by the use of rEEG in their clinics. The physicians received no
remuneration of any kind from CNSR and, in most cases, paid or had
their patients pay for the test and rEEG analysis. After reporting on
their results, a number of these physicians developed a strong desire
to instruct other physicians in the use of rEEG, and they have now
become regional medical directors with responsibility for training
other physicians. These physicians generally reported patient outcomes
on the seven-point scale, Clinical Global Improvement Index. Most also
reported their subjective assessment of the helpfulness of rEEG in
treatment of each patient on a seven-point scale, Clinical Helpfulness
Index. These patients had a wide variety of disorders but were
generally unresponsive to previous treatment efforts. We are pleased
that virtually all reported case series have shown compelling treatment
results with 70% to 90% of patients achieving MUCH IMPROVED or VERY
MUCH IMPROVED rankings. Equally important, similar levels were reported
in the rEEG Helpfulness Index (SIGNIFICANTLY HELPFUL or ESSENTIAL).

MONTE NIDO RESIDENTIAL TREATMENT CENTER
-----------------------------------------------------------------------

Monte Nido is a small in-patient treatment clinic in Malibu,
California, treating patients suffering from significant eating
disorders, primarily anorexia nervosa or bulimia. Dr. W. Hamlin Emory
is Medical Director of this facility. An initial analysis of treatment
results of 81 patients with pharmacotherapy based on rEEG was compared
to 10 patients treated by physicians without rEEG and 13 patients who
had rEEG testing but decided against medication. 83% of the rEEG guided
patient achieved SIGNIFICANT or MARKED improvement. None of the
patients in the other two groups achieved this level of improvement.
These results were published in a Scientific Poster at the National
Institute of Mental Health annual meeting, New Clinical Drug Evaluation
Unit Symposium of 2004. The Monte Nido Residential Treatment Center is
now seeking long term outcome data through patient surveys. We are
looking forward to learning of these results. The initial study was
described in a report in 2001.

HAMILTON-NEWPORT BEACH CASE SERIES
-----------------------------------------------------------------------

Conducted by Dr. Jim Hamilton, a Physician in Newport Beach, CA. In
this study, 34 treatment-resistant patients medicated based on
information provided in rEEG reports were followed and rated. 19 of the
34 patients had addictive disorders. Only 28 of the 34 cases were
analyzed due to the fact that the balance were not available for
follow-up. Of the 28 analyzed, in 22 of these 28 cases rEEG was judged
to be essential or very helpful in their treatment. In 14 out of these
28 cases, where the rEEG was judged essential, Dr. Hamilton reported
that rEEG had directed him "to combinations of medicines that one would
never find, or would take years to find after nothing else had worked."
In the 19 addiction cases, 4 were lost to follow-up, but in the 15 that
were followed, rEEG was judged essential or very helpful in 14 (79%) of
the cases.

HOFFMAN-DENVER CASE SERIES
-----------------------------------------------------------------------

Conducted by Daniel Hoffman, M.D., now a Company Medical Director, with
a practice in Denver, CO. This study was conducted prior to Dr. Hoffman
becoming the National Medical Director for the Company. In this study,
rEEG Analytical Reports were provided for 74 treatment-resistant
patients who were then followed, and were rated on both the CGI scale
and the "Helpfulness" Index. In 56 (74%) of these cases, rEEG was
judged to be essential or very helpful in their treatment. A like
percentage reported a much improved or very much improved on the
Clinical Global Improvement index.

DAVIS-ATLANTA CASE SERIES
-----------------------------------------------------------------------

Conducted by T. Albert Davis, M.D., Medical Director at the Florence
McDonnell Center in Atlanta. This was Dr. Davis's initial study of 15
patients that he treated with the aid of rEEG Reports. All 15 patients
were reported as having successful outcomes with 7 rated as Very Much
Improved and 8 rated Much Improved on the CGI scale. In Helpfulness,
rEEG was rated essential for 9 of these patients and moderately helpful
for six of these patients.

RANCHO L'ABRI DUAL DIAGNOSIS
-----------------------------------------------------------------------

In this study, 58 "dual diagnosis" (addiction and co-morbid mental
illness) patients were treated at Rancho L'Abri, San Diego, one of the
most respected in-patient treatment facilities in Southern California.
The physicians of Rancho L'Abri described their experience with rEEG in
a scientific poster at the 2005 American Psychiatry Association annual
meeting. The poster described both CGI rating of Very Much Improved or
Much Improved and Helpfulness rating of Essential or Very Helpful in
over 90% of the patients for whom it was used.

OUR BUSINESS PLAN - LABORATORY INFORMATION SERVICES

OUR STRATEGY

Our strategy is to provide rEEG analysis in a relationship with a
physician that is analogous to that of a reference laboratory. In each
geographic market, we plan to support this service with a full-time market
manager, identified EEG testing sites and a part-time Regional Medical Director.
The Regional Medical Director will provide local medical leadership and
training, local market communications, a site for physicians to refer
particularly challenging cases and support of family physicians needing
specialty consults.

In the next year, we plan to execute initiatives designed to allow for
dramatic introduction of rEEG to both treating physicians and their patients in
calendar year 2008. We envision this introduction will have elements of pushing
demand for rEEG via physician education and pulling demand for rEEG through
consumer education. The physician introduction will be accomplished through
development of an in-house direct sales force along with professional journal
and trade show introduction. The consumer introduction will utilize the major
broadcast, print and electronic news media.

Certain initiatives which are being considered for 2007 and 2008
include:

1. EXPAND OUR GROUP OF CLIENT-PHYSICIANS TO INCLUDE MOST MAJOR US
CITIES. This key infrastructure development is one element
necessary for rapid penetration. rEEG Reports often stimulate
the identification of treatment strategies that most
physicians would not typically consider. Physicians often are
inexperienced in these treatment strategies, and they

also may be unfamiliar with combinations of medicines that may
be suggested by our rEEG Reports. It is valuable for
physicians who are not familiar with our rEEG Reports to have
an experienced colleague guide them through initial treatments
that are facilitated by the use of our rEEG Reports. For
physicians that are unfamiliar with our rEEG Reports, their
success is dependent on their ability to understand our rEEG
Reports and integrate them as another tool of insight to be
used in conjunction with their existing training.

2. CONDUCT THREE PILOT PROGRAMS WITH MANAGED CARE PAYERS. We
believe that adoption of rEEG for reimbursement is best
accomplished through demonstration of its clinical and
economic impact with patients in a health plan. In at least
one of these pilot programs, CNSR will seek to pay for
independent economic and outcome analysis that CNSR will have
the right to publish. We are currently in discussions with
three MBHOs to conduct our pilot programs.

3. COMPLETE CURRENT MULTI-SITE AND CONDUCT ADDITIONAL ACADEMIC
TRIALS. CNSR is beginning a six site, 100 patient, academic
controlled, blinded, and randomized study of patients
suffering from treatment resistant depression. The study will
be conducted at Stanford, Cambridge Hospital-Harvard,
University of California - Irvine, University of California -
San Diego, University of Texas - San Antonio and University of
British Columbia. This study has been designed with
significant care by many academicians including members of our
advisory board. Because of the involvement of respected
academic centers, we believe that the results of the study
will be published, and widely disseminated. In addition, we
plan to conduct at least two additional clinical trials. We
are also advancing designs in dual-diagnosis addiction and
bulimia, a treatment resistant depression study of different
design and a unique study amongst high performing but
challenged college students.

4. IMPROVE SYSTEM TURN-AROUND TO NEXT DAY AND ADD CAPACITY TO
COVER PROJECTED VOLUME. We plan to increase the usefulness of
our service by returning reports to physicians one day after
patient data is submitted to us. To accomplish this task, we
will need to improve the coordination of functions related to
rEEG analysis that we currently outsource. Our longer term
goal is to advance rEEG turn-around time to be
"while-you-wait."

5. ENHANCE REPORTS TO PROVIDE QUANTITATIVE BIOMARKER DATA AND
DEVELOP PHYSICIAN TRAINING AND CERTIFICATION PROCESS. We plan
to advance our training programs this year with the aid of a
training CD-ROM which is currently in development. In
addition, our next generation rEEG report is anticipated to
provide technical data on the set of rEEG biomarkers in a
manner that will allow trained physicians to better consider
treatment options and integrate their knowledge of clinical
assessment and historical treatment experience with the rEEG
biomarker data. Our training program will aid physicians' use
and understanding of our rEEG Reports. The training process
will have the added advantage of communicating to patients and
their families that a participating physician has completed
rEEG training, and is competent in the use of rEEG Reports to
guide treatment.

6. EXPAND REPORTED MEDICATIONS TO INCLUDE ANTIPSYCHOTICS.
Antipsychotics are the only significant class of psychotropic
medications for which rEEG does not currently offer treatment
guidance. Psychosis is one of the most severe mental illness
and is also one of the most difficult to treat. We plan to
conduct studies to determine if our rEEG Reports are useful in
guiding the treatment of psychosis, especially schizophrenia.
We have two initiatives to accomplish this objective. The
first is a grant from the Washington Technology Center and
Washington State University, and the second is with a group in
China.

7. ADD KEY LEADERSHIP IN MEDICINE AND MARKETING. We plan to
continue to hire, train, retain and motivate additional
skilled personnel, particularly managers with experience in
growing healthcare companies, sales representatives who are
responsible for customer education and training and customer
support, as well as personnel with experience in clinical
testing and matters relating to obtaining regulatory
approvals.

MARKET INTRODUCTION

After accomplishing our immediate goals of building the regional
medical leadership and reaching agreement for pilot trials with MBHOs,
aggressive national introduction will occur with establishment of that regional
leadership, establishment of an introductory sales force, and prepublication
release of our treatment-resistant depression or other key study data.

PUSH: By accessing thought leaders in psychiatry at the national and
community level, publicizing the clinical benefits in professional and consumer
media, and relying on our own dedicated sales force to educate psychiatrists we
believe that the compelling benefits and economic efficiency of rEEG guidance
will provide large scale physician trial.

Our main promotional strategy with physicians will continue to be "try
it, you'll like it - no charge". Because of the low variable cost of producing
rEEG Analytical Reports, we can offer free trials to physicians to encourage
them to begin to experience the benefits of rEEG. Our current program offers
Physicians five (5) free Type I reports with their only commitment being the
completion of a consultative review with one of our regional medical directors
for each report. We encourage physicians to select their most hard to treat
patients for these free trials. It is our expectation that no matter how well
conducted our academic trials, physicians need to experience rEEG for
themselves. One physician has written a letter to CNSR stating, "I DON'T KNOW
THAT I COULD GO BACK TO PRACTICING BLINDED PSYCHIATRY. UNTIL YOU EXPERIENCE HOW
DIFFERENT IT FEELS TO PRACTICE THIS WAY, I COULD SEE SKEPTICISM FROM OTHERS." We
believe physician trial is the key to adoption of rEEG.

PULL: We intend to utilize major print, broadcast and electronic news
media to explain the benefits of rEEG directly to patients. We believe that
these media are the most effective and cost-efficient means to pull-in consumer
demand for rEEG and that we have an unusual opportunity to develop a large reach
at an early stage that can stimulate dynamic demand.

This demand will also encourage physicians to seek early understanding
of rEEG and our goal of trial. Assisting patients to find early adopting
physicians by providing identification of trained physicians on our web site
will likely provide another win- win for patients, physicians and CNSR.

NEW MARKETS

ADDITIONAL APPLICABLE DISORDERS

While physicians have historically classified central nervous system
disorders as psychiatric or neurological, the diseases themselves could be
characterized as disorders of the same organ system, primarily the brain. The
utility of using of neurophysiological data to guide treatment of the brain in
connection with psychiatric disorders may well extend to neurological disorders.

For example, we currently have significant information in our rEEG
Outcomes Database with respect to the effectiveness of anticonvulsants for
patients with certain biomarkers. We intend to explore the utility of our
biomarkers for guiding use of medications, including anticonvulsants, for their
primary

indication of seizure disorders, as well as their utility in pain management for
which they are also often prescribed.

ADDITIONAL APPLICATIONS BEYOND TREATMENT-RESISTANCE

Due to the success of rEEG with treatment-resistant patients, we
believe that rEEG has the potential to become a useful tool for psychiatrists in
treating patients that do not qualify as treatment resistant. For example, it is
generally acknowledged that children have a wide range of reactions to
anti-depressants and, in fact, anti-depressants in many cases actually harm
instead of help them. The ability to avoid prescribing anti-depressants for
children that may have a physiological predisposition to react negatively would
reduce suffering for both the children, and their families, and facilitate the
identification of a successful strategy earlier in the process. In addition,
adolescents, who are typically intolerant of the long process of medication,
would be especially good candidates for rEEG guided therapy.

CENTERS OF EXCELLENCE

It is our intention to work with our Client-Physicians, and our medical
advisors to support, possibly with financial resources, the establishment of
practices and/or clinics that specialize in the use of rEEG guided therapy. We
believe that a network of such practices, which we call "Centers of Excellence,"
will provide opportunities for physician training and additional clinical trials
and demonstrations of the value of rEEG technology. It is our goal to make these
Centers of Excellence a destination for treatment-resistant patients and a
resource for care managers of the MBHOs, and, in time, a network of such Centers
may be in a position to contract for a disease management program with the
managed care industry.

GOVERNMENT

The market for our Laboratory Information Services potentially includes
state hospitals, wards of the state in specialty care homes for persistently and
seriously ill and jails. 2,186,230 prisoners were held in Federal or State
prisons or in local jails as of mid 2005.(17) Rates of severe mental illness in
this population are reportedly as high as 24%.(18) We are not currently pursuing
this market, in part because there is a substantial incidence of Schizophrenia
in this population and we do not yet have sufficient data to provide treatment
guidance for Schizophrenic patients.

We believe the incarcerated population returning to society may be a
particularly good market for rEEG. We have not yet explored the opportunity to
address this population but are interested in studying whether rEEG guided
treatment might add enough improvement in efficiency and effectiveness to alter
the recidivism rate.

RESEARCH AND DEVELOPMENT

We will continue to enhance, refine and improve the accuracy of our
CNSR Database and rEEG through expansion of the number of medications covered by
our rEEG Analytical Reports, expansion of our biomarkers, refinement of our
biomarker system, and by reducing the time to turnaround a report to the
physician. Other specific research and development goals consist of:

o Developing enhanced Type II Analyses that have increased value
and content;

- ----------
(17) U.S. Dept. of Justice- Bureau of Justice Statistics,
http://www.ojp.usdoj.gov/bjs/prisons.htm.

(18) Daly, R., PRISON MENTAL HEALTH CRISIS CONTINUES TO GROW, Psychiatry News,
40-20 at 1 (October 20, 2006).

o Addition of other CNSR agents, and possibly cardiac agents;

o Developing an automated Type I (m) for patients on a single
well characterized medication;

o Advancing our research to understand the total balance
analysis that can be used for monitoring or a more global
scale; and

o Improved graphical presentation of results.

OUR BUSINESS PLAN - PHARMACEUTICAL DEVELOPMENT AND ADVANCEMENT

Although we intend to emphasize our Laboratory Information Services
during the next twelve (12) months, we plan to increase our involvement with the
pharmaceutical industry in the future.

OUR STRATEGY

Our strategy in the next year is the initiation of marketing of rEEG to
selected potential pharmaceutical development partners. Evaluation of such
opportunities by potential partners is complicated by many issues including
state of intellectual property, regulatory approval for marketing and the
trial(s) necessary, medication delivery and packaging requirements of the
medications, therapeutic synergy of the combination, market needs in selected
indications and related competitive advantage, estimated market size, production
costs, current physician familiarity with the individual agents and other
considerations.

A secondary goal is to explore the business opportunity in aiding in
resuscitating opportunities for psychiatric medications that are no longer being
pursued by their developers despite the fact that such medications demonstrated
significant efficacy for subgroups of patients in clinical trials. We believe
that, by using our system of rEEG biomarkers, we can aid in identifying patient
populations that are more likely to respond to a particular medication based on
their common physiological characteristics. We are interested in exploring
cooperative relationships, which utilize our technology and rEEG Outcomes
Database to aid in the development and clinical trials of efficacious
medications that previously had failed to adequately demonstrate that efficacy
in late stage trials.

We intend to leverage our capabilities and technology to develop a
pharmaceutical business from four sources:

COMBINATION OF OFF-PATENT AGENTS FORMULATED INTO SINGLE PILL FIXED-DOSE
COMBINATIONS.

Our data has demonstrated that some patient electrophysiological
abnormalities are more frequently observed than others. Most of the frequent
abnormalities take more than one agent to bring the patient to an
electrophysiological normal state. This is not surprising, as the individual
agents were never developed from an electrophysiological normalizing
perspective. We have identified a number of high frequency abnormalities that
appear to be most effectively addressed by a combination of medications. We have
filed patent applications on two categories of combinations and expect to file
more. Our current focus is for opportunities in bulimia, treatment-resistant
depression and addiction.

PARTNERING WITH PHARMACEUTICAL DEVELOPERS TO "RESCUE" NEW AGENTS IN
DEVELOPMENT.

New Chemical Entities (NCEs) that have been shown to be safe, but not
efficacious in late stage clinical trials present opportunities to partner or
acquire and re-license. Specifically, our interest is focused on a group of
agents that can generally be described as having (a) completed pre-clinical
formulation, toxicology, pilot production development, and all required animal
studies, (b) completed Phase I human safety studies, (c) completed Phase II
human dosing studies and possibly conducted initial

Phase III pivotal efficacy studies. These agents will have shown themselves to
be generally safe without debilitating adverse affects but have been
discontinued in development due to their failure to show compelling efficacy in
either Phase II or Phase III studies.

We estimate that there are approximately 200 central nervous system
compounds which are sitting idle at large pharmaceutical companies after failing
Phase II or Phase III trial.(19) We have completed a review of 53 such agents
that fit the described criteria and initially has focused on eight which are
thought to be worthy of consideration for licensing. Five other agents have been
identified as to be worth in-licensing pursuit for United States development.
These are agents that have been approved in overseas markets but not in the
United States. While they may not have been adequately differentiated, or the
regulatory expense may not have seemed justifiable for the potential market
opportunity, we believe that these agents belong to classes that have been
generally under utilized for additional significant indications. We believe that
for some medications, our rEEG biomarker system will be able to identify
patients with a high likelihood of responding well to these medications based on
the presence of rEEG-defined biomarkers.

We believe our rEEG biomarker system can be used to effect:

o Reduction of placebo responders in a clinical trial by
focusing on treatment resistant patients or eliminating
patients demonstrating normal neurophysiologic function and
balance;

o An increase in treatment group responders by selecting
patients for trial inclusion based on the presence of specific
rEEG defined neurophysiology.

AMELIORATING THE CNSR SIDE EFFECTS OF MEDICATIONS USED FOR OTHER MEDICAL
PURPOSES.

"Cancer fog" is a colloquial term used to describe the response of a
patient or care-givers response to the stresses and perhaps the medications
associated with cancer therapeutics. For patients, these effects appear to be
particularly specific to certain chemotherapeutic agents.

To the extent these agents cause a specific common alteration in
neurophysiological function, rEEG should be able to note and identify this. This
should allow the creation of a counteracting medication antidote for people
suffering from a neuropsychiatric condition following primary therapy.

COMPARABLE COMPANIES, COMPETITION AND INDUSTRY DEVELOPMENTS

INDUSTRY DEVELOPMENTS

We are not aware of any reference laboratories that service Psychiatry
with tools or information to direct therapy, although the following firms are
using neurophysiological data in an attempt to diagnose certain disorders and,
in some cases, monitor or confirm therapy:

o LEXICOR INC. (www.lexicor.com) uses EEG to diagnose ADHD

- ----------
(19) Jarvis, L. M. TEACHING AN OLD DRUG NEW TRICKS: GENE LOGIC IS CONVINCING BIG
PHARMA TO TAKE ANOTHER LOOK AT ABANDONED DRUGS. Chemical and Engineering
News, 84-7 at 52,54-55(February 13, 2006).

o NEURONETIX (www.neuronetix.com) uses tools to diagnose Autism,
Dyslexia and Alzheimer's

o AMEN CLINIC - uses SPECT for diagnosis and monitoring of
therapy

o NEUROGNOSTICS - uses FMRI for confirmation of therapeutic
efficacy

We are not aware of any companies using neurophysiological data to
guide therapy in conjunction with a neurophysiology outcomes database.

COMPARABLE COMPANIES

Although there are no companies offering a service similar to that
offered by CNSR, the following companies might be noted as comparable through
some commonalities:

o ASPECT MEDICAL SYSTEMS, INC. (Nasdaq: ASPM), an EEG anesthesia
monitoring company, is developing a specific EEG measurement
system that indicates a patient's likely response to some
antidepressant medications. Boston Scientific invested $25
million in a joint venture to accelerate this effort. Patients
must be measured prior to and after taking medication.
Publicly available knowledge suggests that the technology may
validate a patient's treatment but does not guide specific
treatment. Initial trials have shown efficacy in correlating a
patient's ultimate response to antidepressants. The revenue
model appears to involve sale of equipment and a per-patient
charge. The company is now conducting trials.

o HYTHIAM, INC. (Nasdaq: HYTM). Though perhaps more of an
analogous company than a competitor, Hythiam is a public
company introducing a proprietary addiction detoxification
procedure that purports to address physiologic needs of
addicts and impact on-going recovery. The company charges a
$15,000 fee for stimulant abusers and $12,000 for alcohol
abusers. Since CNSR does not provide guidance regarding
detoxification of addictions (only their post-detoxification
treatment), Hythiam is not a direct competitor.

o BRAIN RESOURCE COMPANY (www.brainresource.com), a development
stage Australian public company developing EEG and other
physiology data on patients with behavioral illness through a
network of physician data relationships. Their revenue model
includes physician services and sale of systems and services
to pharmaceutical development companies in the CNSR field.

o GENOMIC HEALTH, INC. (NasdaqGM: GHDX). This public company
provides analogous services to those of CNSR for patients
suffering from cancer.

EMERGING TECHNOLOGIES

The entire field of neuropsychiatry is undergoing dramatic changes as a result
of the introduction of new technologies. Many of these changes are driven by
medical device companies including:

o CYBERONICS, INC. (Nasdaq: CYBX). Cyberonics has developed an
implantable Vagus Nerve Stimulation device approved for
treatment-resistant depression. This device has received
pre-marketing approval from the Food and Drug Agency for
patients and is believed to be under reimbursement review by
insurance payers.

o MEDTRONIC, INC. (NYSE: MDT). Medtronic has an implantable deep
brain stimulation device (DBS) in development which is similar
to their device approved for Parkinson's treatment.

o NEURONETICS (www.neuronetics.com). Neuronetics has developed a
trans-cranial magnetic stimulation (rTMS) device which is
designed to be applied externally in a series of treatments
over several weeks. The company is expected to file FDA
registration soon.

We view these developing treatment options as expensive augmentations
to existing therapies for treatment-resistant patients. From this perspective,
these devices can be considered as competitive therapeutic treatment options to
medications. To the best of our knowledge, rEEG-guided therapy provides a higher
probability of treatment success at a significantly lower cost than device-based
solutions, which gives us a competitive advantage in the marketplace.

GOVERNMENT REGULATION

In the future, we intend to seek approval for medications or
combinations of medications for new indications, either with corporate partners,
or potentially, on our own. The development and commercialization of medications
for new indications is subject to extensive regulation by the U.S. Federal
government, principally through the FDA and other federal, state and
governmental authorities elsewhere. Prior to marketing any central nervous
system medication, and in many cases prior to being able to successfully partner
a central nervous system medication, we will have to conduct extensive clinical
trials at our own expense to determine safety and efficacy of the indication
that we are pursuing.

EMPLOYEES

As of March 7, 2007, we had 7 full-time employees. Since inception, we
have never had a work stoppage, and our employees are not represented by a labor
union. We consider our relationships with our employees to be positive.

LEGAL PROCEEDINGS

From time to time, we may be involved in litigation relating to claims
arising out of our operations in the normal course of business. We are not
currently party to any legal proceedings, the adverse outcome of which, in our
management's opinion, individually or in the aggregate, that would have a
material adverse effect on our results of operations or financial position.

DESCRIPTION OF PROPERTY.

We currently lease our office space under a lease agreement which
expires in April of 2007. The facility is approximately 1900 sq. ft, and is
located in Costa Mesa, California. It is from this facility that we conduct all
of our executive and administrative functions. We believe our space is adequate
for our current needs and that suitable additional or substitute space will be
available to accommodate the foreseeable expansion of our operations. Our
telephone number is (949) 248-5461.

FILING STATUS

We file reports with the Securities and Exchange Commission the
("SEC"). You can read and copy any materials we file with the Commission at its'
Public Reference Room at 450 Fifth Street, NW, Washington, DC 20549. You can
obtain additional information about the operation of the Public Reference Room
by calling the Commission at 1-800-SEC-0330. In addition, the Commission
maintains an Internet site (www.sec.gov) that contains reports, proxy and
information statements, and other information regarding issuers that file
electronically with the Commission, including us.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS

THIS DISCUSSION SUMMARIZES THE SIGNIFICANT FACTORS AFFECTING THE
OPERATING RESULTS, FINANCIAL CONDITION AND LIQUIDITY AND CASH FLOWS OF CNSR
CALIFORNIA FOR THE FISCAL YEARS ENDED SEPTEMBER 30, 2006 AND 2005, AND THE THREE
MONTH PERIODS ENDED DECEMBER 31, 2006 AND 2005. THE DISCUSSION AND ANALYSIS THAT
FOLLOWS SHOULD BE READ TOGETHER WITH OUR FINANCIAL STATEMENTS AND THE NOTES TO
THE FINANCIAL STATEMENTS INCLUDED ELSEWHERE IN THIS FORM 8-K. EXCEPT FOR
HISTORICAL INFORMATION, THE MATTERS DISCUSSED IN THIS MANAGEMENT'S DISCUSSION
AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS ARE FORWARD
LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES AND ARE BASED UPON
JUDGMENTS CONCERNING VARIOUS FACTORS THAT ARE BEYOND OUR CONTROL.

OVERVIEW

We are a life sciences company focused on the commercialization of a
patented system that guides psychiatrists and other physicians to determine a
proper treatment for patients with behavioral (psychiatric, and/or addictive
disorders). We also intend to identify, develop and commercialize new
indications of approved drugs and drug candidates for this patient population.

We have developed an extensive proprietary database ("CNS Database")
consisting of approximately 13,000 clinical outcomes across 2,000 patients who
had psychiatric or addictive problems. For each patient, we have compiled
electrocephalographic ("EEG") scans, symptoms, course of treatment and outcomes
often across multiple treatments from multiple psychiatrists and physicians.
Using this database, our technology compares a patient's EEG scan to the
outcomes in the database and ranks treatment options based on treatment success
of patients having similar neurophysiology.

Trademarked as Referenced-EEGSM ("rEEGSM"), this patented technology
allows CNS to create and provide simple reports that specifically guide
physicians to treatment strategies based on the patient's own physiology. The
vast majority of these patients were considered long-term "treatment-resistant",
the most challenging, high-risk and expensive category to treat.

rEEG identifies relevant neurophysiology that is variant from the
norm and identifies medications that have successfully treated database patients
having similar aberrant physiology. It does this by comparing a patient's
standard digital EEG to a normative database. This identifies the presence of
any pathophysiology. The rEEG process then compares the stratified set of
patients with similar pathophysiology to our CNS Database and reports on
relative medication success for this stratified group. Upon completion, the
physician is provided the analysis in a report detailing and ranking classes of
agents (and specific agents within the class) by treatment success.

We believe the key factors that will drive broader adoption of rEEG
will be acceptance by healthcare providers of its clinical benefits,
demonstration of the cost-effectiveness of using our test, reimbursement by
third-party payors, expansion of our sales force and increased marketing
efforts.

Since our inception, we have generated significant net losses. As of
December 31, 2006, we had an accumulated deficit of $8.4 million. We incurred
operating losses of $400,000 for the quarter ended December 31, 2006 and $1.8
million and $1.0 million in the years ended September 30, 2006 and 2005,
respectively. We expect our net losses to continue for at least the next several
years. We anticipate that a substantial portion of our capital resources and
efforts will be focused on research and development, scale up our commercial
organization, and other general corporate purposes. Research and development
projects include the completion of clinical trials, the enhancement of our
database and the identification of new medication that are often combinations of
approved drugs.

FINANCIAL OPERATIONS OVERVIEW

REVENUES

We derive our revenues from the sale of rEEG Analytical Reports to
physicians and operate in one industry segment. Physicians are generally billed
upon delivery of an rEEG Analytical Report. The list prices of our rEEG
Analytical Reports to physicians range from $200 to $800 with $400 being the
most frequent charge.

COST OF REVENUES

Cost of revenues represents the cost of direct labor, the amortization
of the purchased database and costs associated with external processing,
analysis and consulting review necessary to render an individualized test
result. Costs associated with performing our tests are expensed as the tests are
performed. We are currently evaluating the feasibility of hiring our own
personnel to perform most of the processing and analysis necessary to render a
report.

RESEARCH AND DEVELOPMENT

Research and development expenses primarily represent costs incurred to
design and conduct clinical studies, improve rEEG processing, add data to our
database, improve analytical techniques and advance application of the
methodology to additional clinical diagnosis. We charge all research and
development expenses to operations as they are incurred.

SALES AND MARKETING

Our selling and marketing expenses consist primarily of personnel costs
and the costs of educating physicians, laboratory personnel and other healthcare
professionals regarding our product.

GENERAL AND ADMINISTRATIVE

Our general and administrative expenses consist primarily of personnel
related costs, legal costs, accounting costs and other professional and
administrative costs.

CRITICAL ACCOUNTING POLICIES AND SIGNIFICANT JUDGMENTS AND ESTIMATES

This discussion and analysis of our financial condition and results of
operations is based on our financial statements, which have been prepared in
accordance with U.S. generally accepted accounting principles. The preparation
of these financial statements requires management to make estimates and
judgments that affect the reported amounts of assets, liabilities and expenses
and the disclosure of contingent assets and liabilities at the date of the
financial statements, as well as revenues and expenses during the reporting
periods. We evaluate our estimates and judgments on an ongoing basis. We base
our

estimates on historical experience and on various other factors we believe are
reasonable under the circumstances, the results of which form the basis for
making judgments about the carrying value of assets and liabilities that are not
readily apparent from other sources. Actual results could therefore differ
materially from those estimates under different assumptions or conditions.

Our significant accounting policies are described in the notes to our
financial statements included elsewhere in this report. We believe the following
critical accounting policies reflect our more significant estimates and
assumptions used in the preparation of our financial statements.

REVENUE RECOGNITION

We have generated limited revenues since our inception. Revenues for
our product are recognized when an rEEG Analytical Report is delivered to a
Client-Physician.

STOCK-BASED COMPENSATION EXPENSE

Stock-based compensation expense, which is a non-cash charge, results
from stock option grants. Compensation cost is measured at the grant date based
on the calculated fair value of the award. We recognize stock-based compensation
expense on a straight-line basis over the vesting period of the underlying
option. The amount of stock-based compensation expense expected to be amortized
in future periods may decrease if unvested options are subsequently cancelled or
may increase if future option grants are made.

RESULTS OF OPERATIONS FOR THE QUARTERS ENDED DECEMBER 31, 2006 AND 2005

FOR THE THREE MONTHS ENDED
DECEMBER 31,
---------------------------
2006 2005
--------- ---------
Revenues ................................... $ 46,600 $ 36,600
--------- ---------

Operating expenses:
Cost of revenues ........................ 47,000 33,300
Research and development ................ 180,100 89,000
Sales and marketing ..................... 26,000 11,000
General and administrative .............. 194,200 146,800
--------- ---------

Total operating expenses ............... 447,300 280,100
--------- ---------

Operating loss ............................. (400,700) (243,500)

Other income (expense) ..................... 800 (97,300)
--------- ---------

Loss before income taxes ................... (399,900) (340,800)
Income taxes ............................... -- --
Net loss ................................... $(399,900) $(340,800)
========= =========

REVENUES-Revenues were $46,600 for the quarter ended December 31, 2006
as compared to $36,600 for the comparable period in 2005. The increase in
revenues resulted from the adoption of rEEG by an additional eight (8)
physicians. The number of rEEG's performed in the quarter increased from 97 in
2005 to 123 in 2006 while the price per test remained constant at approximately
$380. To drive broader adoption of rEEG we have undertaken a multi-site clinical
study to validate the efficacy of our

product. In addition, we plan to increase our marketing efforts and expand our
sales force to increase market awareness of rEEG.

COST OF REVENUES-For the quarter ended December 31, 2006, cost of
revenues was $47,000, consisting primarily of direct labor costs of $15,800,
consulting fees of $11,300 and amortization of the purchased database of
$19,900. For the quarter ended December 31, 2005, cost of revenues was $33,300
consisting primarily of direct labor costs of $12,600, consulting fees of $800
and amortization of the purchased database of $19,900. We expect costs of
revenues will increase as an absolute number as the volume of rEEGs processed
increases; however, cost of revenues will decrease as a percentage of revenues
due to operating efficiencies and since the cost of the purchased database has
been amortized fully in the quarter ended December 31, 2006.

RESEARCH AND DEVELOPMENT-Research and development expenses were
$180,100 for the quarter ended December 31, 2006 as compared to $89,000 for the
comparable period in 2005. The increase in research and development expenses of
$91,100 is primarily attributable to additional costs of $36,300 incurred in
connection with research for the identification of indications of approved drugs
and drug candidates and the cost of $59,700 to conduct clinical studies in 2006.
We expect research and development expenses to continue to increase as we
continue with the identification of approved drugs and drug candidates, complete
studies to validate the efficacy of our product, acquire new data for our
database, enhance our system and hire additional employees.

SALES AND MARKETING- Sales and marketing expenses were $26,000 for the
quarter ended December 31, 2006 as compared to $11,000 for the comparable period
in 2005. The increase in sales and marketing expenses resulted primarily from
increased payroll costs and the design of marketing materials in the quarter
ended December 31,2006. We expect sales and marketing expenses to increase
substantially as we increase our marketing efforts and expand our sales.

GENERAL AND ADMINISTRATIVE- General and administrative expenses were
$194,200 for the quarter ended December 31, 2006 as compared to $146,800 for the
comparable period in 2005. The increase in general and administrative resulted
primarily from an increase in legal and accounting costs associated with the
reverse merger. We expect general and administrative costs to increase as we
expand our staff and incur costs associated with being a public company.

INTEREST EXPENSE-Interest expense was $51,000 for the quarter ended
December 31, 2006 as compared to $97,300 for the comparable period in 2005. The
decrease in interest expense resulted from the conversion of promissory notes
into the Company's preferred stock in October 2006.

RESULTS OF OPERATIONS FOR THE YEARS ENDED SEPTEMBER 30, 2006 AND 2005

For the years ended
September 30,
------------------------------
2006 2005
----------- -----------
Revenues ................................. $ 175,500 $ 127,400
----------- -----------

Operating expenses:
Cost of revenues ....................... 175,900 165,100
Research and development ............... 76,700 58,500
Sales and marketing .................... 36,000 52,900
General and administrative ............. 1,671,100 811,800
----------- -----------

Total operating expenses ............. 1,959,700 1,088,300
----------- -----------

Operating loss ........................... (1,784,200) (960,900)
----------- -----------

Other income (expense):
Interest expense, net .................. (390,600) (330,700)
Gain (loss) on derivative
instruments .......................... 1,178,500 (212,500)
Gain on troubled debt
restructuring ........................ 1,079,700 --
----------- -----------
Total other income
(expense) .......................... 1,867,600 (543,200)
----------- -----------

Income (Loss) before income
taxes .................................. 83,400 (1,504,100)
Income taxes ............................. 800 800
----------- -----------
Net income (loss) ....................... $ 82,600 $(1,504,900)
=========== ===========

REVENUES-Revenues were $175,500 for the year ended September 30, 2006
as compared to $127,400 for the comparable period in 2005. The increase in
revenues resulted from the adoption of rEEG by additional physicians. To drive
broader adoption of rEEG we have undertaken a clinical study to validate the
efficacy of rEEG, and intend to increase our marketing efforts and expand our
sales force.

COST OF REVENUES-For the year ended September 30, 2006, cost of
revenues was $175,900, consisting primarily of direct labor costs of $50,200,
consulting fees of $41,500 and amortization of the purchased database of
$79,800. For the year ended September 30, 2005, cost of revenues was $165,100
consisting primarily of direct labor costs of $50,200, consulting fees of
$25,000 and amortization of the purchased database of $79,800. We expect costs
of revenues will increase as an absolute number as the volume of rEEGs processed
increases; however, cost of revenues will decrease as a percentage of revenues
due to operating efficiencies and as a result of the cost of the purchased
database being fully amortized in the first quarter of our fiscal year ending
September 30, 2007.

RESEARCH AND DEVELOPMENT-Research and development expenses were $76,700
for the year ended September 30, 2006 as compared to $58,500 for the comparable
period in 2005. The increase in research and development expenses resulted from
increased consulting fees incurred in 2006 primarily related to the design of
clinical studies. We expect research and development expenses to increase as we
complete studies to validate the efficacy of our product, acquire new data for
our database, enhance our system and hire additional employees.

SALES AND MARKETING- Sales and marketing expenses were $36,000 for the
year ended September 30, 2006 as compared to $52,900 for the comparable period
in 2005. The decrease in sales and marketing expenses resulted from a decrease
in sales consultants in 2006. We expect sales and marketing to increase as we
increase our marketing efforts and expand our sales.

GENERAL AND ADMINISTRATIVE- General and administrative expenses were
$1,671,100 for the year ended September 30, 2006 as compared to $811,800 for the
comparable period in 2005. The increase in general and administrative resulted
from an increase in payroll costs of $420,300, an increase in legal and
accounting costs of $248,400 and an increase in consulting fees of $123,900. We
expect general and administrative costs to increase as we expand our staff and
incur costs associated with being a public company.

INTEREST EXPENSE-Interest expense was $390,600 for the year ended
September 30, 2006 as compared to $330,700 for the comparable period in 2005.
The increase in interest expense resulted from an increase in interest-bearing
debt including convertible promissory notes, deferred salaries and unreimbursed
expenses. We expect interest expenses to decrease, as substantially all of our
interest-bearing debt was repaid or converted into equity in October 2006.

GAIN (LOSS) ON DERIVATIVE INSTRUMENTS-Gain on derivative instruments
was $1,178,500 for the year ended September 30, 2006 compared to a loss of
$212,500 for the comparable period in 2005. In accordance with generally
accepted accounting principles, we treated the beneficial conversion feature
associated with the convertible promissory notes and all non-employee warrants
exercisable during the period the notes were potentially convertible into an
unlimited number of common shares as liabilities at their fair value. The fair
value of the beneficial conversion feature and the warrants were estimated using
the Black-Scholes option pricing model. The fair value of the beneficial
conversion feature and the warrants and options was recomputed each reporting
period with the change in fair value recorded as a gain or loss on derivative
instruments.

GAIN ON TROUBLED DEBT RESTRUCTURING-Gain on troubled debt restructuring
was $1,079,700 for the year ended September 30, 2006 as compared to zero in the
comparable period for 2005. At September 30, 2005, we owed certain employees and
consultants deferred compensation, accrued consulting fees, other
compensation-related liabilities and accrued interest thereon aggregating
$2,480,900. Due to financial difficulties experienced by the company, in August
and September 2006, certain employees and consultants to whom the company owed
an aggregate of $3,199,400 accepted 5,834,117 shares of CNSR California's common
stock (of which 182,952 were restricted), and warrants and options to purchase
an aggregate of 270,638 shares of CNSR California's common stock at $0.59 per
share in full settlement of our obligations. On the date of transfer, the
amounts due to employees and consultants exceeded the aggregate fair value of
the shares, warrants and options transferred by $2,467,700. The gain
attributable to employees considered related parties of $1,388,000 has been
treated as a capital transaction and included in additional paid-in capital in
the accompanying financial statements. The remaining gain of $1,079,700 has been
included in operations in the accompanying financial statements.

LIQUIDITY AND CAPITAL RESOURCES

Since our inception, we have incurred significant losses and, as of
December 31, 2006, we had an accumulated deficit of approximately $8.4 million.
We have not yet achieved profitability and anticipate that we will continue to
incur net losses for the foreseeable future. We expect that our research and
development, selling and marketing and general and administrative expenses will
continue to grow and, as a result, we will need to generate significant product
revenues to achieve profitability. We may never achieve profitability.

SOURCES OF LIQUIDITY-Since our inception substantially all of our
operations have been financed primarily from debt financings. Through December
31, 2006, we had received proceeds of $3,116,000 from the issuance of
convertible promissory notes, $220,400 from the issuance of common stock to
employees in connection with expenses paid by such employees on behalf of the
company, and $1.9 million from the sale of preferred stock. As of December 31,
2006, we had cash of $1.4 million and debt of $1.2 million. On March 7, 2007, we
merged with CNS Response, Inc., a Delaware company (formerly called
Strativation, Inc.), and concurrently therewith received gross proceeds of
approximately $7,008,450 in a private placement transaction (the "Private
Placement") with institutional investors and other high net worth individuals
("Investors"). Pursuant to Subscription Agreements entered into with these
Investors, we sold 5,840,374 Investment Units, at $1.20 per Investment Unit.
Each "Investment Unit" consists of one share of our common stock, and a five
year non-callable warrant to purchase three-tenths of one share of our common
Stock, at an exercise price of $1.80 per share (the "Investor Warrant"). We may
agree to sell additional Investment Units for a period of 45 days following
March 7, 2007, so that the gross proceeds from the offering may be in excess of
$7,008,450.

CASH FLOWS-As of December 31, 2006 we had $1.4 million in cash compared
to $314,800 at December 31, 2005. The increase of $1.1 million was due primarily
to cash provided from the sale of our preferred stock offset by the use of
$529,700 in cash in our operating activities.

Net cash used in operating activities was $530,000 for the quarter
ended December 31, 2006 compared to $163,000 for the comparable period in 2005.
The increase in cash used of $367,000 was primarily due to increases in research
and development expenses and general and administrative expenses, and the
inability of the Company to pay its obligations as of December 31, 2005.

Net cash used in investing activities was $5,400 for the quarter ended
December 31, 2006 compared to zero for the comparable period in 2005. Our
investing activities for the quarter consisted of lease deposits and loans made
to employees. We expect amounts used in investing activities to increase as we
purchase property and equipment.

Net cash provided by financing activities was $1.7 million for the
quarter ended December 31, 2006 compared to $0 for the comparable period in
2005. Financing activities consisted primarily of the sale of preferred stock.

CONTRACTUAL OBLIGATIONS-As of December 31, 2006, we had no significant
contractual obligations.

OPERATING CAPITAL AND CAPITAL EXPENDITURE REQUIREMENTS-We expect to
continue to incur substantial operating losses in the future and to make capital
expenditures to keep pace with the expansion of our research and development
programs and to scale up our commercial operations. We expect that our existing
cash will be used to fund working capital and for capital expenditures and other
general corporate purposes. The amount and timing of actual expenditures may
vary significantly depending upon a number of factors, such as the progress of
our product development, regulatory requirements, commercialization efforts and
the amount of cash used by operations.

We currently anticipate that our cash and collections from sale of our
services, together with the proceeds of completed financings, including the
Private Placement, will be sufficient to fund our operations for at least the
next 12 months.

Our future funding requirements will depend on many factors, including
the following:

a. the cost of expanding our commercial operations, including our
selling and marketing efforts;

b. the rate of progress and cost of research and development
activities associated with our products;

c. the rate of progress and cost of research and development
activities associated with the identification, development and
commercialization of new indications of approved drugs and
drug candidates;

d. the cost of filing, prosecuting, defending and enforcing our
patents and other intellectual property rights; and

e. the effect of technological and market developments.

Until we can generate a sufficient amount of revenues to finance our
cash requirements, which we may never do, we expect to finance future cash needs
primarily through public or private equity offerings, debt financings,
borrowings or strategic collaborations. The issuance of equity securities may
result in dilution to stockholders. We do not know whether additional funding
will be available on acceptable terms, or at all. If we are not able to secure
additional funding when needed, we may have to delay, reduce the scope of or
eliminate one or more research and development programs or selling and marketing
initiatives. In addition, we may have to work with a partner on one or more of
our technology development programs or market development programs, which may
lower the economic value of those programs to our company.

INCOME TAXES- Since inception, we have incurred operating losses and,
accordingly, have not recorded a provision for federal income taxes for any
periods presented. As of September 30, 2006, we had net operating loss
carryforwards for federal income tax purposes of $4,627,600. If not utilized,
the federal net operating loss carryforwards will expire beginning in 2021.
Utilization of net operating loss and credit carryforwards may be subject to a
substantial annual limitation due to restrictions contained in the Internal
Revenue Code that are applicable if we experience an "ownership change" that may
occur, for example, as a result of the Private Placement being aggregated with
certain other sales of our stock before or after this offering. The annual
limitation may result in the expiration of our net operating loss and tax credit
carryforwards before they can be used.

YOU SHOULD CAREFULLY CONSIDER THE FOLLOWING RISK FACTORS AND ALL OTHER
INFORMATION CONTAINED IN THIS REPORT BEFORE PURCHASING SHARES OF OUR COMMON
STOCK. INVESTING IN OUR COMMON STOCK INVOLVES A HIGH DEGREE OF RISK. IF ANY OF
THE FOLLOWING EVENTS OR OUTCOMES ACTUALLY OCCURS, OUR BUSINESS OPERATING RESULTS
AND FINANCIAL CONDITION WOULD LIKELY SUFFER. AS A RESULT, THE TRADING PRICE OF
OUR COMMON STOCK COULD DECLINE, AND YOU MAY LOSE ALL OR PART OF THE MONEY YOU
PAID TO PURCHASE OUR COMMON STOCK.

RISK FACTORS

RISKS RELATED TO OUR COMPANY

WE HAVE A LIMITED OPERATING HISTORY, MAKING IT DIFFICULT TO EVALUATE OUR FUTURE
PERFORMANCE.

We were incorporated in 2000 and therefore have a limited operating
history. Investors have limited substantive financial information on prior
operations to evaluate the company as an investment. Our potential must be
viewed in light of the problems, expenses, difficulties, delays and
complications often encountered in the operation of a new business. We will be
subject to the risks inherent in the ownership and operation of a company with a
limited operating history such as fluctuations in expenses, competition, the
general strength of regional and national economies, and governmental
regulation. Any failure to successfully address these risks and uncertainties
would seriously harm our business and prospects.

WE CURRENTLY DEPEND ON SALES OF OUR REEG ANALYTICAL REPORTS FOR SUBSTANTIALLY
ALL OF OUR REVENUE, AND IF OUR REPORTS DO NOT GAIN WIDESPREAD MARKET ACCEPTANCE,
THEN OUR REVENUES MAY NOT EXCEED OUR EXPENSES.

We have developed a methodology that aids psychiatrists and other
physicians in selecting appropriate and effective medications for patients with
certain behavioral or addictive disorders based on physiological traits of the
patient's brain and information contained in a proprietary database that has
been developed over the last twenty years. We began selling reports, referred to
as rEEG Analytical Reports, based on our methodology in 2000. To date, we have
not received widespread market acceptance of the usefulness of our rEEG
Analytical Reports in helping psychiatrists and physicians inform their
treatment strategies for patients suffering from behavioral and/or addictive
disorders. Because we currently depend on the sale of rEEG Analytical Reports
for substantially all or our revenue, and we have no other significant products
or services, if we fail to achieve widespread market acceptance for our rEEG
Analytical Reports, we will not be able to sustain or grow our revenues.

OUR OPERATING RESULTS MAY FLUCTUATE SIGNIFICANTLY AND OUR STOCK PRICE COULD
DECLINE OR FLUCTUATE IF OUR RESULTS DO NOT MEET THE EXPECTATION OF ANALYSTS OR
INVESTORS.

Management expects that we will experience substantial variations in
our operating results from quarter to quarter. We believe that the factors which
influence this variability of quarterly results include:

o the use of and demand for rEEG Analytical Reports and other
products and/or services that we may offer in the future that
are based on our patented methodology.

o the effectiveness of new marketing and sales programs.

o turnover in our direct sales force.

o changes in management.

o the introduction of products or services that are viewed in
the marketplace as substitutes for the services we provide.

o communications published by industry organizations or other
professional entities in the psychiatric and physician
community that are unfavorable to our business.

o the introduction of regulations which impose additional costs
on or impede our business.

o the timing and amount of our expenses, particularly expenses
associated with the marketing and promotion of our services,
the training of physicians and psychiatrists in the use of our
rEEG Analytical Reports, and research and development.

As a result of fluctuations in our revenue and operating expenses that
may occur, management believes that period-to-period comparisons of our results
of operations are not a good indication of our future performance. It is
possible that in some future quarter or quarters, our operating results will be
below the expectations of securities analysts or investors. In that case, our
common stock price could fluctuate significantly or decline.

IF THE ESTIMATES WE MAKE, AND THE ASSUMPTIONS ON WHICH WE RELY IN PREPARING OUR
FINANCIAL STATEMENTS PROVE INACCURATE, OUR ACTUAL RESULTS MAY VARY FROM THOSE
REFLECTED IN OUR FINANCIAL STATEMENTS.

Our financial statements have been prepared in accordance with
accounting principles generally accepted in the United States. The preparation
of these financial statements requires us to make estimates and judgments that
affect the reported amounts of our assets, liabilities, revenues and expenses,
the amounts of charges accrued by us and related disclosure of contingent assets
and liabilities. This includes estimates and judgments regarding revenue
recognition, allowances for doubtful accounts, valuation of derivatives,
warrants and other equity transactions. We base our estimates and judgments on
historical experience and on various other assumptions that we believe to be
reasonable under the circumstances at the time such estimates and judgments were
made. There can be no assurance, however, that our estimates and judgments, or
the assumptions underlying them, will be correct.

WE MAY NEED ADDITIONAL FUNDING TO SUPPORT OUR OPERATIONS AND CAPITAL
EXPENDITURES, WHICH MAY NOT BE AVAILABLE TO US AND WHICH LACK OF AVAILABILITY
COULD ADVERSELY AFFECT OUR BUSINESS.

We have not generated significant revenues or become profitable, may
never do so, and may not generate sufficient working capital to cover costs of
operations. We intend to fund our operations and capital expenditures from
revenues, our cash on hand and the net proceeds of our Private Placement. As a
result of our Private Placement, we believe that we will have sufficient funds
to finance the cost of our operations, our operating and management
infrastructure, and planned expansion for the next 15 months. However, in the
event we expand our operations more aggressively then we currently anticipate,
we may need additional capital for this purpose. In addition, we may need
additional funds to pursue business opportunities (such as acquisitions of
complementary businesses), to react to unforeseen difficulties, such as the need
to defend or enforce our intellectual property rights, to respond to competitive
pressures, or to obtain regulatory approvals needed to market our Laboratory
Information Services and other services and/or products.

If our capital resources are insufficient, we will need to raise
additional funds. We currently have no committed sources of additional capital,
and there can be no assurance that any financing arrangements

will be available in amounts or on terms acceptable to us, if at all.
Furthermore, the sale of additional equity or convertible debt securities may
result in additional dilution to existing stockholders. If adequate additional
funds are not available, we may be required to delay, reduce the scope of or
eliminate material parts of the implementation of our business strategy. This
limitation could substantially harm our business, results of operations and
financial condition.

OUR INDUSTRY IS HIGHLY COMPETITIVE, AND WE MAY NOT BE ABLE TO COMPETE
SUCCESSFULLY, WHICH COULD RESULT IN PRICE REDUCTIONS AND DECREASED DEMAND FOR
OUR PRODUCTS.

The healthcare business in general, and the behavioral health treatment
business in particular, are highly competitive. In the event that we are unable
to convince physicians, psychiatrists and patients of the efficacy of our
products and services, particularly our Laboratory Information Services,
individuals seeking treatment for behavioral health disorders may seek
alternative treatment methods, which could negatively impact our sales and
profitability.

OUR LABORATORY INFORMATION SERVICES MAY NOT BE AS EFFECTIVE AS WE BELIEVE THEM
TO BE, WHICH COULD LIMIT OR PREVENT US FROM GROWING OUR REVENUES.

Our belief in the efficacy of our Laboratory Information Services that
we provide is based on a limited number of studies. Such results may not be
statistically significant, and may not be indicative of the long-term future
efficacy of the information we provide. Controlled scientific studies, including
those that have been announced and that are planned for the future, may yield
results that are unfavorable or demonstrate that our Laboratory Information
Services are not clinically useful. While we have not experienced such problems
to date, if the initially indicated results cannot be successfully replicated or
maintained over time, utilization of our Laboratory Information Services could
decline substantially.

DATA RELATING TO OUR PRODUCTS AND SERVICES MAY BE INTERPRETED UNFAVORABLY, WHICH
COULD ADVERSELY AFFECT OUR REVENUES AND EARNINGS.

While we have been able to generate initial interest in our Laboratory
Information Services among a limited number of psychiatrists and physicians,
there can be no assurance that our efforts or the efforts of others will be
successful in increasing the acceptance of our Laboratory Information Services.
Marketplace acceptance of our Laboratory Information Services may largely depend
upon healthcare providers' interpretation of our limited data, the results of
pending studies, or upon reviews and reports that may be given by independent
researchers. In the event that health care providers interpret data relating to
our Laboratory Information Services unfavorably, and if our marketing and
promotional efforts are not as successful as we expect them to be, our revenues
and earnings will be harmed.

IF WE DO NOT MAINTAIN AND EXPAND OUR RELATIONSHIPS IN THE PSYCHIATRIC AND
PHYSICIAN COMMUNITY, OUR GROWTH WILL BE LIMITED AND OUR BUSINESS COULD BE
HARMED. IF PSYCHIATRISTS AND OTHER PHYSICIANS DO NOT RECOMMEND AND ENDORSE OUR
PRODUCTS AND SERVICES, OUR SALES MAY DECLINE OR WE MAY BE UNABLE TO INCREASE OUR
SALES, AND IN SUCH INSTANCES OUR PROFITABILITY WOULD BE HARMED.

Purchases by psychiatrists and physicians of our Laboratory Information
Services currently account for substantially all of our revenue. Consequently,
our relationships with psychiatrists and physicians are critical to our
continued growth. We believe that these relationships are based on the quality
and ease of use of our Laboratory Information Services, our commitment to the
behavioral health market, our marketing efforts, and our presence at tradeshows
such as the American Psychiatric Association annual meeting. Any actual or
perceived diminution in our reputation or the quality of our Laboratory
Information Services, or our failure or inability to maintain our commitment to
the behavioral health market and our other marketing and product promotion
efforts could damage our current

relationships, or prevent us from forming new relationships, with psychiatrists
and other physicians and cause our growth to be limited and our business to be
harmed.

To sell our Laboratory Information Services, psychiatric professionals
must recommend and endorse them. We may not obtain the necessary recommendations
or endorsements from this community. Acceptance of our Laboratory Information
Services depends on educating psychiatrists and physicians as to the benefits,
clinical efficacy, ease of use, revenue opportunity, and cost-effectiveness of
our Laboratory Information Services and on training the medical community to
properly understand and utilize our rEEG Analytical Reports. If we are not
successful in obtaining the recommendations or endorsements of psychiatrists and
other physicians for our Laboratory Information Services, our sales may decline
or we may be unable to increase our sales and profitability.

NEGATIVE PUBLICITY OR UNFAVORABLE MEDIA COVERAGE COULD DAMAGE OUR REPUTATION AND
HARM OUR OPERATIONS.

In the event that the marketplace perceives our Laboratory Information
Services as not offering the benefits which we believe they offer, we may
receive significant negative publicity. This publicity may result in litigation
and increased regulation and governmental review. If we were to receive such
negative publicity or unfavorable media attention, whether warranted or
unwarranted, our ability to market our Laboratory Information Services would be
adversely affected, pharmaceutical companies may be reluctant to pursue
strategic initiatives with us relating to the development of new products and
services, we may be required to change our products and services and become
subject to increased regulatory burdens, and we may be required to pay large
judgments or fines. Any combination of these factors could further increase our
cost of doing business and adversely affect our financial position, results of
operations and cash flows.

IF WE DO NOT SUCCESSFULLY GENERATE ADDITIONAL PRODUCTS AND SERVICES FROM OUR
PATENTED METHODOLOGY AND PROPRIETARY DATABASE, OR IF SUCH PRODUCTS AND SERVICES
ARE DEVELOPED BUT NOT SUCCESSFULLY COMMERCIALIZED, THEN WE COULD LOSE REVENUE
OPPORTUNITIES.

Currently, our primary business is the sale of Laboratory Information
Services to psychiatrists and physicians based on our rEEG methodology and
proprietary database. In the future, we may utilize our patented methodology and
proprietary database to produce pharmaceutical advancements and developments.
For instance, we may use our patented methodology and proprietary database to
identify new medications that are promising in the treatment of behavioral
health disorders, identify new uses of medications which have been previously
approved, and identify new patient populations that are responsive to
medications in clinical trials that have previously failed to show efficacy in
United States Food & Drug Administration (FDA) approved clinical trials. The
development of new pharmaceutical applications that are based on our patented
methodology and proprietary database will be costly, since we will be subject to
additional regulations, including the need to conduct expensive and time
consuming clinical trials.

In addition, to successfully monetize our pharmaceutical opportunity,
we will need to enter into strategic alliances with biotechnology or
pharmaceutical companies that have the ability to bring to market a medication,
an ability which we currently do not have. We maintain no pharmaceutical
manufacturing, marketing or sales organization, nor do we plan to build one in
the foreseeable future. Therefore, we are reliant upon approaching and
successfully negotiating attractive terms with a partner who has these
capabilities. No guarantee can be made that we can do this on attractive terms.
If we are unable to find strategic partners for our pharmaceutical opportunity,
our revenues may not grow as quickly as we desire, which could lower our stock
price.

IN THE EVENT THAT WE PURSUE OUR PHARMACEUTICAL OPPORTUNITIES, WE OR ANY
DEVELOPMENT PARTNERS THAT WE PARTNER WITH WILL LIKELY NEED TO CONDUCT CLINICAL
TRIALS. IF SUCH CLINICAL TRIALS ARE DELAYED OR UNSUCCESSFUL, IT COULD HAVE AN
ADVERSE EFFECT ON OUR BUSINESS.

We have no experience conducting clinical trials of psychiatric
medications and in the event we conduct clinical trials, we will rely on outside
parties, including academic investigators, outside consultants and contract
research organizations to conduct these trials on our behalf. We will rely on
these parties to assist in the recruitment of sites for participation in
clinical trials, to maintain positive relations with these sites, and to ensure
that these sites conduct the trials in accordance with the protocol and our
instructions. If these parties renege on their obligations to us, our clinical
trials may be delayed or unsuccessful.

In the event we conduct clinical trials, we cannot predict whether we
will encounter problems that will cause us or regulatory authorities to delay or
suspend our clinical trials or delay the analysis of data from our completed or
ongoing clinical trials. In addition, we cannot assure you that we will be
successful in reaching the endpoints in these trials, or if we do, that the FDA
or other regulatory agencies will accept the results.

Any of the following could delay the completion of clinical trials, or
result in a failure of these trials to support our business, which would have an
adverse effect on our business:

o delays or the inability to obtain required approvals from
institutional review boards or other governing entities at
clinical sites selected for participation in our clinical
trials,

o delays in enrolling patients and volunteers into clinical
trials,

o lower than anticipated retention rates of patients and
volunteers in clinical trials,

o negative results from clinical trials for any of our potential
products, and

o failure of our clinical trials to demonstrate the efficacy or
clinical utility of our potential products.

If we determine that the costs associated with attaining regulatory
approval of a product exceed the potential financial benefits or if the
projected development timeline is inconsistent with our determination of when we
need to get the product to market, we may chose to stop a clinical trial and/or
development of a product.

IF WE DO NOT DEVELOP AND IMPLEMENT A SUCCESSFUL SALES AND MARKETING STRATEGY, WE
MAY NOT EXPAND OUR BUSINESS SUFFICIENTLY TO COVER OUR EXPENSES.

We currently rely on our direct sales force to market and promote our
Laboratory Information Services. In the event that we experience high turnover
in our direct sales force, and new sales representatives do not acquire the
skills to sell our Laboratory Information Services in a timely and successful
manner, we may not be able to sustain and grow our revenue.

In addition, in order to grow our business, we will need to develop and
introduce new sales and marketing programs and clinical education programs to
promote the use of our Laboratory Information Services by psychiatrists and
physicians. If we do not implement these new sales and marketing and education
programs in a timely and successful manner, we may not be able to achieve the
level of market awareness and sales required to expand our business.

WE MAY NOT BE ABLE TO GENERATE ENOUGH ADDITIONAL REVENUE FROM ANY INTERNATIONAL
EXPANSION TO OFFSET THE COSTS ASSOCIATED WITH ESTABLISHING AND MAINTAINING
FOREIGN OPERATIONS.

Currently, we do not have any international operations. However, a
component of our growth strategy is to expand our presence into international
markets. It is costly to establish international facilities and operations and
to promote our Laboratory Information Services in international markets. We may
encounter barriers to the sale of our Laboratory Information Services outside
the United States, including reduced acceptance by psychiatrists and physicians
of our Laboratory Information Services, delays in regulatory approvals outside
of the United States, and difficulties associated with establishing sales
channels. In addition, we have little experience in marketing and distributing
our Laboratory Information Services in international markets. Revenue from
international activities may not offset the expense of establishing and
maintaining these international operations.

WE MAY NOT BE ABLE TO MEET THE UNIQUE OPERATIONAL, LEGAL AND FINANCIAL
CHALLENGES THAT WE WILL ENCOUNTER IN OUR INTERNATIONAL OPERATIONS, WHICH MAY
LIMIT THE GROWTH OF OUR BUSINESS.

If and when we expand internationally, we will be subject to a number
of challenges which specifically relate to our international business
activities. These challenges include:

o failure of local laws to provide adequate protection against
infringement of our intellectual property

o protectionist laws and business practices that favor local
competitors, which could slow our growth in international
markets,

o less acceptance by psychiatrists and physicians of the use of
our products and services,

o delays in regulatory approval of our products or services,

o currency conversion issues arising from sales denominated in
currencies other than the United States dollar,

o foreign currency exchange rate fluctuations,

o longer accounts receivable payment cycles and difficulties in
collecting accounts receivable.

If we are unable to meet and overcome these challenges, our
international operations may not be successful which would limit the growth of
our business and could adversely impact our results of operations.

WE MAY FAIL TO SUCCESSFULLY MANAGE AND MAINTAIN THE GROWTH OF OUR BUSINESS,
WHICH COULD ADVERSELY AFFECT OUR RESULTS OF OPERATIONS.

As we continue expanding our commercial operations, this expansion
could place significant strain on our management, operational, and financial
resources. To manage future growth, we will need to continue to hire, train, and
manage additional employees, particularly a specially trained sales force to
market our Laboratory Information Services.

In addition, we have maintained a small financial and accounting staff,
and our reporting obligations as a public company, as well as our need to comply
with the requirements of the Sarbanes-Oxley Act of 2002, and the rules and
regulations of the SEC will continue to place significant demands on

our financial and accounting staff, on our financial, accounting and information
systems and on our internal controls. As we grow, we will need to add additional
accounting staff and continue to improve our financial, accounting and
information systems and internal controls in order to fulfill our reporting
responsibilities and to support expected growth in our business. Our current and
planned personnel, systems, procedures and controls may not be adequate to
support our anticipated growth or management may not be able to effectively
hire, train, retain, motivate and manage required personnel. Our failure to
manage growth effectively could limit our ability to achieve our marketing and
commercialization goals or to satisfy our reporting and other obligations as a
public company.

WE MAY INCUR SIGNIFICANT EXPENSES OR BE PREVENTED FROM COMMERCIALIZING OR
DEVELOPING PRODUCTS AS A RESULT OF AN INTELLECTUAL PROPERTY INFRINGEMENT CLAIM.

Our commercial success depends, in part, on our ability to operate
without infringing the patents and proprietary rights of third parties.
Infringement proceedings are long, costly and time-consuming and their outcome
is uncertain.

If we become involved in any patent infringement litigation,
interference or other administrative proceedings related to our intellectual
property, we will incur substantial expenses and the time and effort of our
management and scientific personnel, will be significantly diverted. As a result
of such litigation or proceedings, we could lose our proprietary position, and
be restricted from selling, manufacturing or distributing the affected
product(s), incur substantial damage awards, including punitive damages, or be
required to seek third party licenses at terms that may be unattractive, or we
may fail to acquire the license.

WE MAY NOT BE ABLE TO ADEQUATELY PROTECT OUR INTELLECTUAL PROPERTY, WHICH IS THE
CORE OF OUR BUSINESS.

We consider the protection of our intellectual property to be critical
to our business prospects. We currently have two issued U.S. patents, and we
have filed separate patent applications in multiple foreign jurisdictions.

In the future, if we fail to file patent applications in a timely
manner, or in the event we elect not to file a patent application because of the
costs associated with patent prosecution, we may lose patent protection that we
may have otherwise obtained. The loss of any proprietary rights which are
obtainable under patent laws may result in the loss of a competitive advantage
over present or potential competitors, with a resulting decrease in revenues and
profitability for us.

With respect to the applications we have filed, there is no guarantee
that the applications will result in issued patents, and further, any patents
that do issue may be too narrow in scope to adequately protect our intellectual
property and provide us with a competitive advantage. Competitors and others may
design around aspects of our technology, or alternatively may independently
develop similar or more advanced technologies that can be used in the treatment
of behavioral health disorders that fall outside the scope of our claimed
subject matter.

In addition, even if we are issued additional patents covering our
products, we cannot predict with certainty whether or not we will be able to
enforce our proprietary rights, and whether our patents will provide us with
adequate protection against competitors. We may be forced to engage in costly
and time consuming litigation or reexamination proceedings to protect our
intellectual property rights, and our opponents in such proceedings may have and
be willing to expend, substantially greater resources than we are able to. In
addition, the results of such proceedings may result in our patents being
invalidated or reduced in scope. These developments could cause a decrease in
our operating income and reduce our available cash flow, which could harm our
business and cause our stock price to decline.

We also utilize processes and technology that constitute trade secrets,
such as our outcomes database, and we must implement appropriate levels of
security for those trade secrets to secure the protection of applicable laws,
which we may not do effectively. In addition, the laws of many foreign countries
do not protect proprietary rights as fully as the laws of the United States.

While we have not had any significant issues to date, the loss of any
of our trade secrets or proprietary rights which may be protected under the
foregoing intellectual property safeguards may result in the loss of our
competitive advantage over present and potential competitors.

CONFIDENTIALITY AGREEMENTS WITH EMPLOYEES, LICENSEES AND OTHERS MAY NOT
ADEQUATELY PREVENT DISCLOSURE OF TRADE SECRETS AND OTHER PROPRIETARY INFORMATION

In order to protect our proprietary technology and processes, we rely
in part on confidentiality provisions in our agreements with employees,
licensees, treating physicians and psychiatrists and others. These agreements
may not effectively prevent disclosure of confidential information and may not
provide an adequate remedy in the event of unauthorized disclosure of
confidential information. Moreover, policing compliance with our confidentiality
agreements and non-disclosure agreements, and detecting unauthorized use of our
technology is difficult, and we may be unable to determine whether piracy of our
technology has occurred. In addition, others may independently discover trade
secrets and proprietary information. Costly and time-consuming litigation could
be necessary to enforce and determine the scope of our proprietary rights, and
failure to obtain or maintain trade secret protection could adversely affect our
competitive business position.

ALTHOUGH WE BELIEVE WE ARE NOT CURRENTLY SUBJECT TO REGULATORY APPROVAL FOR THE
SALE OF OUR LABORATORY INFORMATION SERVICES, REGULATIONS ARE CONSTANTLY
CHANGING, AND IN THE FUTURE OUR BUSINESS MAY BE SUBJECT TO REGULATION.

Currently, we do not believe that sales of our Laboratory Information
Services, including our rEEG Analytical Reports, are subject to regulatory
approval. However, federal, state and foreign laws and regulations relating to
the sale of our Laboratory Information Services are subject to future changes,
as are administrative interpretations of regulatory agencies. If we fail to
comply with applicable federal, state or foreign laws or regulations, we could
be subject to enforcement actions, including injunctions preventing us from
conducting our business, withdrawal of clearances or approvals and civil and
criminal penalties. In the event that federal, state, and foreign laws and
regulations change, we may need to incur additional costs to seek government
approvals for our Laboratory Information Services. There is no guarantee that we
will be able to obtain such approvals in a timely manner or at all, and as a
result, our revenues from our Laboratory Information Services may be reduced, or
potentially eliminated.

IN THE FUTURE, WE INTEND TO SEEK REGULATORY APPROVAL FOR MEDICATIONS OR
COMBINATIONS OF MEDICATIONS FOR NEW INDICATIONS, AND THERE IS NO GUARANTEE THAT
WE WILL RECEIVE SUCH APPROVALS.

We intend to seek approval for medications or combinations of
medications for new indications, either with corporate partners, or potentially,
on our own. We are currently not authorized to market such medications in any
jurisdiction, and we may never receive such authorization. The development and
commercialization of medications for new indications is subject to extensive
regulation by the U.S. Federal government, principally through the FDA and other
federal, state and governmental authorities elsewhere. Prior to marketing any
central nervous system medication, and in many cases prior to being able to
successfully partner a central nervous system medication, we will have to
conduct extensive clinical trials at our own expense to determine safety and
efficacy of the indication that we are pursuing. We have no prior experience, as
a company, in conducting clinical trials. Clinical trials are expensive and can
take years to complete, and have uncertain outcomes. In addition, the regulatory
and approval procedures vary from country to country, and additional testing may
be required in some jurisdictions. It may take several years to complete the
clinical trials, and a product may fail at any stage of testing. Difficulties
and risks associated with clinical trials may result in our, or our partners'
inability to achieve regulatory approval to market medications for central
nervous system disorders. The FDA, other regulatory agencies, our collaborators,
or we may suspend or terminate clinical trials at any time.

Delays or failures in obtaining regulatory approval may delay or
prevent the commercialization of any product that we may develop for new
indications, diminish any competitive advantage, reduce or eliminate revenues,
milestone payments or royalties from collaborators, and adversely affect our
ability to attract new collaborators. The results of earlier clinical trials do
not necessarily predict the results of later clinical trials. Medications in
later clinical trials may fail to show desired safety and efficacy traits in the
indication we are seeking approval for, despite prior success in clinical trials
for other indications. Even if we and/or our collaborators and partners believe
the data collected from such clinical trials are promising, such data may not
support approval by the FDA or any other regulatory authorities. In addition,
the FDA or other regulatory authority may interpret the data differently than we
do, which could delay, limit or prevent regulatory approval. We expect to rely,
in part, on clinical trials that were performed by third-party physicians. These
trial results may not be predictive of the results of clinical trials we intend
to perform for new indications. In addition, the results of prior clinical
trials may not now be acceptable to the FDA or other regulatory authorities
because the data may be incomplete, outdated, or otherwise unacceptable for
inclusions in ours or our partners' regulatory submissions for approval of
medications for new indications.

IN THE EVENT WE OBTAIN REGULATORY APPROVAL FOR NEW INDICATIONS FOR EXISTING
MEDICATIONS, WE WILL STILL BE SUBJECT TO EXTENSIVE REGULATION BY THE FDA AND
OTHER AGENCIES, AND IF WE FAIL TO COMPLY WITH SUCH REGULATIONS, THE SALE OF OUR
PRODUCTS MAY BE RESTRICTED.

If we, or our collaborators, obtain regulatory approval for new
indications for existing medications, we will still be subject to extensive
regulation by the FDA and/or other regulatory agencies. We and our collaborators
will be required to conduct extensive post-market surveillance of products. Our,
or our collaborators', failure to comply with applicable FDA and other
regulatory requirements, or the later discovery of unknown problems, may result
in restrictions on the marketing or sale of such products that will negatively
impact sales and/or collaboration revenue, and may result in denial of authority
to market the medication product(s).

IF WE DO NOT RETAIN OUR SENIOR MANAGEMENT AND OTHER KEY EMPLOYEES, WE MAY NOT BE
ABLE TO SUCCESSFULLY IMPLEMENT OUR BUSINESS STRATEGY.

Our future success depends on the on the ability, experience and
performance of our senior management and our key professional personnel. Our
success therefore depends to a significant extent on retaining the services of
Leonard Brandt, our President, Chief Executive Officer, and Secretary, Horace
Hertz, our Chief Financial Officer, and others. Because of their ability and
experience, if we lose one or more of the members of our senior management or
other key employees, our ability to successfully implement our business strategy
could be seriously harmed.

We intend to carry key man life insurance on Leonard Brandt in an
amount of $2.0 million, payable to the company. We do not carry key man life
insurance on any of our other key employees. We do not have employment
agreements in place with our executives and key employees, and each may
terminate their employment upon notice and without cause or good reason. While
we believe our relationships with our executives are good and do not anticipate
any of them leaving in the near future, the loss of the services of Leonard
Brandt or any other key member of management could have a material adverse
effect on our ability to manage our business.

IF WE DO NOT ATTRACT AND RETAIN SKILLED PERSONNEL OR IF WE DO NOT MAINTAIN GOOD
RELATIONSHIPS WITH OUR EMPLOYEES, WE MAY NOT BE ABLE TO EXPAND OUR BUSINESS.

Our products and services are based on a complex database of
information. Accordingly, we require skilled medical, scientific and
administrative personnel to sell and support our products and services. Our
future success will depend largely on our ability to continue to hire, train,
retain and motivate additional skilled personnel, particularly sales
representatives who are responsible for customer education and training and
customer support, as well as personnel with experience in clinical testing and
matters relating to obtaining regulatory approvals. If we are not able to
attract and retain skilled personnel, we will not be able to continue our
development and commercialization activities.

In addition, we may be subject to claims that we engage in
discriminatory or inappropriate practices with respect to our hiring,
termination, promotion and compensation processes for our employees. Such
claims, with or without merit, could be time consuming, distracting and
expensive to defend, could divert attention of our management from other tasks
important to the success of our business and could adversely affect our
reputation as an employer.

IN THE FUTURE WE COULD BE SUBJECT TO PERSONAL INJURY CLAIMS, WHICH COULD RESULT
IN SUBSTANTIAL LIABILITIES THAT MAY EXCEED OUR INSURANCE COVERAGE.

All significant medical treatments and procedures, including treatment
that is facilitated through the use of our Laboratory Information Services,
involve the risk of serious injury or death. While we do not treat patients or
determine whether treatment that is guided by the Laboratory Information
Services that we provide is appropriate for any particular patient, and have not
been the subject of any personal injury claims for patients treated by providers
using our Laboratory Information Services, our business entails an inherent risk
of claims for personal injuries, which are subject to the attendant risk of
substantial damage awards. We cannot control whether individual physicians and
psychiatrists will properly select patients, apply the appropriate standard of
care, or conform to our procedures in determining how to treat their patients. A
significant source of potential liability is negligence or alleged negligence by
physicians treating patients with the aid of the Laboratory Information Services
we provide. There can be no assurance that a future claim or claims will not be
successful or, including the cost of legal defense, will not exceed the limits
of available insurance coverage.

We currently have general liability and medical professional liability
insurance coverage for up to $5 million per year for personal injury claims. We
may not be able to maintain adequate liability insurance, in accordance with
standard industry practice, with appropriate coverage based on the nature and
risks of our business, at acceptable costs and on favorable terms. Insurance
carriers are often reluctant to provide liability insurance for new healthcare
services companies and products due to the limited claims history for such
companies and products. In addition, based on current insurance markets, we
expect that liability insurance will be more difficult to obtain and that
premiums will increase over time and as the volume of patients treated by
physicians that are guided by our Laboratory Information Services increases. In
the event of litigation, regardless of its merit or eventual outcome, or an
award against us during a time when we have no available insurance or
insufficient insurance, we may sustain significant losses of our operating
capital which may substantially reduce stockholder equity in the company.

IF GOVERNMENT AND THIRD-PARTY PAYERS FAIL TO PROVIDE COVERAGE AND ADEQUATE
PAYMENT RATES FOR TREATMENTS THAT ARE GUIDED BY OUR LABORATORY INFORMATION
SERVICES, OUR REVENUE AND PROSPECTS FOR PROFITABILITY MAY BE HARMED.

Our future revenue growth will depend in part upon the availability of
reimbursement from third-party payers for psychiatrists and physicians who use
our Laboratory Information Services to guide the treatment of their patients.
Such third-party payers include government health programs such as Medicare and
Medicaid, managed care providers, private health insurers and other
organizations. These third-party payers are increasingly attempting to contain
healthcare costs by demanding price discounts or rebates and limiting both
coverage on which procedures they will pay for and the amounts that they will
pay for new procedures. As a result, they may not cover or provide adequate
payment for treatments that are guided by our Laboratory Information Services,
which will discourage psychiatrists and physicians from utilizing the
information services we provide. We may need to conduct studies to demonstrate
the cost-effectiveness of treatments that are guided by our products and
services to such payers' satisfaction. Such studies might require us to commit a
significant amount of management time and financial and other resources.
Adequate third-party reimbursement might not be available to enable us to
realize an appropriate return on investment in research and product development,
and the lack of such reimbursement could have a material adverse effect on our
operations and could adversely affect our revenues and earnings.

OUR BUSINESS PROSPECTS AND PROFITABILITY COULD BE NEGATIVELY IMPACTED IF WE HAVE
OVER-ESTIMATED THE DEMAND FOR OUR LABORATORY INFORMATION SERVICES.

We are focused on the market for behavioral health disorders. The
projected demand for our Laboratory Information Services could materially differ
from actual demand if our assumptions regarding this market and its trends and
acceptance of our Laboratory Information Services by the psychiatric community
prove to be incorrect or do not materialize or if other products or services
gain more widespread acceptance, which in each case would adversely affect our
business prospects and profitability.

WE ARE SUBJECT TO EVOLVING AND EXPENSIVE CORPORATE GOVERNANCE REGULATIONS AND
REQUIREMENTS. OUR FAILURE TO ADEQUATELY ADHERE TO THESE REQUIREMENTS OR THE
FAILURE OR CIRCUMVENTION OF OUR CONTROLS AND PROCEDURES COULD SERIOUSLY HARM OUR
BUSINESS.

Because we are a publicly traded company we are subject to certain
federal, state and other rules and regulations, including applicable
requirements of the Sarbanes-Oxley Act of 2002. Compliance with these evolving
regulations is costly and requires a significant diversion of management time
and attention, particularly with regard to our disclosure controls and
procedures and our internal control over

financial reporting. Although we have reviewed our disclosure and internal
controls and procedures in order to determine whether they are effective, our
controls and procedures may not be able to prevent errors or frauds in the
future. Faulty judgments, simple errors or mistakes, or the failure of our
personnel to adhere to established controls and procedures may make it difficult
for us to ensure that the objectives of the control system are met. A failure of
our controls and procedures to detect other than inconsequential errors or fraud
could seriously harm our business and results of operations.

OUR SENIOR MANAGEMENT'S LIMITED RECENT EXPERIENCE MANAGING A PUBLICLY TRADED
COMPANY MAY DIVERT MANAGEMENT'S ATTENTION FROM OPERATIONS AND HARM OUR BUSINESS.

Our management team has relatively limited recent experience managing a
publicly traded company and complying with federal securities laws, including
compliance with recently adopted disclosure requirements on a timely basis. Our
management will be required to design and implement appropriate programs and
policies in responding to increased legal, regulatory compliance and reporting
requirements, and any failure to do so could lead to the imposition of fines and
penalties and harm our business.

RISKS RELATED TO OUR INDUSTRY

THE HEALTHCARE INDUSTRY IN WHICH WE OPERATE IS SUBJECT TO SUBSTANTIAL REGULATION
BY STATE AND FEDERAL AUTHORITIES, WHICH COULD HINDER, DELAY OR PREVENT US FROM
COMMERCIALIZING OUR PRODUCTS AND SERVICES.

Healthcare companies are subject to extensive and complex federal,
state and local laws, regulations and judicial decisions governing various
matters such as the licensing and certification of facilities and personnel, the
conduct of operations, billing policies and practices, policies and practices
with regard to patient privacy and confidentiality, and prohibitions on payments
for the referral of business and self-referrals. There are federal and state
laws, regulations and judicial decisions that govern patient referrals,
physician financial relationships, submission of healthcare claims and
inducement to beneficiaries of federal healthcare programs. Many states prohibit
business corporations from practicing medicine, employing or maintaining control
over physicians who practice medicine, or engaging in certain business
practices, such as splitting fees with healthcare providers. Many healthcare
laws and regulations applicable to our business are complex, applied broadly and
subject to interpretation by courts and government agencies. Our failure, or the
failure of physicians and psychiatrists to whom we sell our Laboratory
Information Services, to comply with these healthcare laws and regulations could
create liability for us and negatively impact our business.

In addition, the FDA, regulates development, testing, labeling,
manufacturing, marketing, promotion, distribution, record-keeping and reporting
requirements for prescription drugs. Compliance with laws and regulations
enforced by the FDA and other regulatory agencies may be required in relation to
future products or services developed or used by us. Failure to comply with
applicable laws and regulations may result in various adverse consequences,
including withdrawal of our products and services from the market, or the
imposition of civil or criminal sanctions.

We believe that this industry will continue to be subject to increasing
regulation, political and legal action and pricing pressures, the scope and
effect of which we cannot predict. Legislation is continuously being proposed,
enacted and interpreted at the federal, state and local levels to regulate
healthcare delivery and relationships between and among participants in the
healthcare industry. Any such changes could prevent us from marketing some or
all of our products and services for a period of time or permanently.

WE MAY BE SUBJECT TO REGULATORY AND INVESTIGATIVE PROCEEDINGS, WHICH MAY FIND
THAT OUR POLICIES AND PROCEDURES DO NOT FULLY COMPLY WITH COMPLEX AND CHANGING
HEALTHCARE REGULATIONS.

While we have established policies and procedures that we believe will
be sufficient to ensure that we operate in substantial compliance with
applicable laws, regulations and requirements, the criteria are often vague and
subject to change and interpretation. We may become the subject of regulatory or
other investigations or proceedings, and our interpretations of applicable laws
and regulations may be challenged. The defense of any such challenge could
result in substantial cost and a diversion of management's time and attention.
Thus, any such challenge could have a material adverse effect on our business,
regardless of whether it ultimately is successful. If we fail to comply with any
applicable laws, or a determination is made that we have failed to comply with
these laws, our financial condition and results of operations could be adversely
affected.

FAILURE TO COMPLY WITH THE FEDERAL TRADE COMMISSION ACT OR SIMILAR STATE LAWS
COULD RESULT IN SANCTIONS OR LIMIT THE CLAIMS WE CAN MAKE.

The Company's promotional activities and materials, including
advertising to consumers and physicians, and materials provided to third parties
for their use in promoting our products and services, are regulated by the
Federal Trade Commission (FTC) under the FTC Act, which prohibits unfair and
deceptive acts and practices, including claims which are false, misleading or
inadequately substantiated. The FTC typically requires competent and reliable
scientific tests or studies to substantiate express or implied claims that a
product or service is effective. If the FTC were to interpret our promotional
materials as making express or implied claims that our products and services are
effective for the treatment of mental illness, it may find that we do not have
adequate substantiation for such claims. Failure to comply with the FTC Act or
similar laws enforced by state attorneys general and other state and local
officials could result in administrative or judicial orders limiting or
eliminating the claims we can make about our products and services, and other
sanctions including fines.

OUR BUSINESS PRACTICES MAY BE FOUND TO CONSTITUTE ILLEGAL FEE-SPLITTING OR
CORPORATE PRACTICE OF MEDICINE, WHICH MAY LEAD TO PENALTIES AND ADVERSELY AFFECT
OUR BUSINESS.

Many states, including California, in which our principal executive
offices are located, have laws that prohibit business corporations, such as us,
from practicing medicine, exercising control over medical judgments or decisions
of physicians, or engaging in certain arrangements, such as employment or
fee-splitting, with physicians. Courts, regulatory authorities or other parties,
including physicians, may assert that we are engaged in the unlawful corporate
practice of medicine by providing administrative and ancillary services in
connection with our Laboratory Information Services, or that selling our rEEG
Analytical Reports for a portion of the patient fees constitutes improper
fee-splitting, in which case we could be subject to civil and criminal
penalties, our contracts could be found legally invalid and unenforceable, in
whole or in part, or we could be required to restructure our contractual
arrangements. There can be no assurance that this will not occur or, if it does,
that we would be able to restructure our contractual arrangements on favorable
terms.

OUR BUSINESS PRACTICES MAY BE FOUND TO VIOLATE ANTI-KICKBACK, SELF-REFERRAL OR
FALSE CLAIMS LAWS, WHICH MAY LEAD TO PENALTIES AND ADVERSELY AFFECT OUR
BUSINESS.

The healthcare industry is subject to extensive federal and state
regulation with respect to financial relationships and "kickbacks" involving
healthcare providers, physician self-referral arrangements, filing of false
claims and other fraud and abuse issues. Federal anti-kickback laws and
regulations prohibit certain offers, payments or receipts of remuneration in
return for (i) referring patients covered by Medicare, Medicaid or other federal
health care program, or (ii) purchasing, leasing, ordering

or arranging for or recommending any service, good, item or facility for which
payment may be made by a federal health care program. In addition, federal
physician self-referral legislation, commonly known as the Stark law, generally
prohibits a physician from ordering certain services reimbursable by Medicare,
Medicaid or other federal healthcare program from any entity with which the
physician has a financial relationship. In addition, many states have similar
laws, some of which are not limited to services reimbursed by federal healthcare
programs. Other federal and state laws govern the submission of claims for
reimbursement, or false claims laws. One of the most prominent of these laws is
the federal False Claims Act, and violations of other laws, such as the
anti-kickback laws or the FDA prohibitions against promotion of off-label uses
of medications, may also be prosecuted as violations of the False Claims Act.

While we believe we have structured our relationships to comply with
all applicable requirements, federal or state authorities may claim that our fee
arrangements, agreements and relationships with contractors and physicians
violate these anti-kickback, self-referral or false claims laws and regulations.
These laws are broadly worded and have been broadly interpreted by courts. It is
often difficult to predict how these laws will be applied, and they potentially
subject many typical business arrangements to government investigation and
prosecution, which can be costly and time consuming. Violations of these laws
are punishable by monetary fines, civil and criminal penalties, exclusion from
participation in government-sponsored health care programs and forfeiture of
amounts collected in violation of such laws. Some states also have similar
anti-kickback and self-referral laws, imposing substantial penalties for
violations. If our business practices are found to violate any of these
provisions, we may be unable to continue with our relationships or implement our
business plans, which would have an adverse effect on our business and results
of operations.

WE MAY BE SUBJECT TO HEALTHCARE ANTI-FRAUD INITIATIVES, WHICH MAY LEAD TO
PENALTIES AND ADVERSELY AFFECT OUR BUSINESS.

State and federal governments are devoting increased attention and
resources to anti-fraud initiatives against healthcare providers, taking an
expansive definition of fraud that includes receiving fees in connection with a
healthcare business that is found to violate any of the complex regulations
described above. While to our knowledge we have not been the subject of any
anti-fraud investigations, if such a claim were made defending our business
practices could be time consuming and expensive, and an adverse finding could
result in substantial penalties or require us to restructure our operations,
which we may not be able to do successfully.

OUR USE AND DISCLOSURE OF PATIENT INFORMATION IS SUBJECT TO PRIVACY AND SECURITY
REGULATIONS, WHICH MAY RESULT IN INCREASED COSTS

In conducting research or providing administrative services to
healthcare providers in connection with the use of our Laboratory Information
Services, we may collect, use, maintain and transmit patient information in ways
that will be subject to many of the numerous state, federal and international
laws and regulations governing the collection, dissemination, use and
confidentiality of patient-identifiable health information, including the
federal Health Insurance Portability and Accountability Act (HIPAA) and related
rules. The three rules that were promulgated pursuant to HIPAA that could most
significantly affect our business are the Standards for Electronic Transactions,
or Transactions Rule; the Standards for Privacy of Individually Identifiable
Health Information, or Privacy Rule; and the Health Insurance Reform: Security
Standards, or Security Rule. HIPAA applies to covered entities, which include
most healthcare facilities and health plans that may contract for the use of our
services. The HIPAA rules require covered entities to bind contractors like us
to compliance with certain burdensome HIPAA rule requirements.

The HIPAA Transactions Rule establishes format and data content
standards for eight of the most common healthcare transactions. If we perform
billing and collection services on behalf of psychiatrists and physicians, we
may be engaging in one of more of these standard transactions and will be
required to conduct those transactions in compliance with the required
standards. The HIPAA Privacy Rule restricts the use and disclosure of patient
information, requires entities to safeguard that information and to provide
certain rights to individuals with respect to that information. The HIPAA
Security Rule establishes elaborate requirements for safeguarding patient
information transmitted or stored electronically. We may be required to make
costly system purchases and modifications to comply with the HIPAA rule
requirements that are imposed on us and our failure to comply may result in
liability and adversely affect our business.

Numerous other federal and state laws protect the confidentiality of
personal and patient information. These laws in many cases are not preempted by
the HIPAA rules and may be subject to varying interpretations by courts and
government agencies, creating complex compliance issues for us and the
psychiatrists and physicians who purchase our services, and potentially exposing
us to additional expense, adverse publicity and liability. Other countries also
have, or are developing, laws governing the collection, use and transmission of
personal or patient information and these laws could create liability for us or
increase our cost of doing business.

RISKS RELATING TO INVESTMENT IN OUR COMMON STOCK

WE HAVE A LIMITED TRADING VOLUME AND SHARES ELIGIBLE FOR FUTURE SALE BY OUR
CURRENT STOCKHOLDERS MAY ADVERSELY AFFECT OUR STOCK PRICE.

Bid and ask prices for shares of our Common Stock are quoted on NASD's
OTC Bulletin Board under the symbol CNSO.OB. There is currently no broadly
followed, established trading market for our Common Stock. While we are hopeful
that following the Merger, the Company will command the interest of a greater
number of investors, an established trading market for our shares of Common
Stock may never develop or be maintained. Active trading markets generally
result in lower price volatility and more efficient execution of buy and sell
orders. The absence of an active trading market reduces the liquidity of our
Common Stock. Before commencement of the Private Placement, we had little or no
trading volume in our Common Stock. As a result of this lack of trading
activity, the quoted price for our Common Stock on NASD's OTC Bulletin Board is
not necessarily a reliable indicator of its fair market value. Further, if we
cease to be quoted, holders would find it more difficult to dispose of, or to
obtain accurate quotations as to the market value of, our Common Stock, and the
market value of our Common Stock would likely decline.

IF AND WHEN A TRADING MARKET FOR OUR COMMON STOCK DEVELOPS, THE MARKET PRICE OF
OUR COMMON STOCK IS LIKELY TO BE HIGHLY VOLATILE AND SUBJECT TO WIDE
FLUCTUATIONS, AND YOU MAY BE UNABLE TO RESELL YOUR SHARES AT OR ABOVE THE PRICE
AT WHICH YOU ACQUIRED THEM.

The market price of our Common Stock is likely to be highly volatile
and could be subject to wide fluctuations in response to a number of factors
that are beyond our control, including announcements of new products or services
by our competitors. In addition, the market price of the Common Stock could be
subject to wide fluctuations in response to a variety of factors, including:

o quarterly variations in our revenues and operating expenses;

o developments in the financial markets and worldwide or
regional economies;

o announcements of innovations or new products or services by us
or our competitors;

o announcements by the government relating to regulations that
govern our industry;

o significant sales of our Common Stock or other securities in
the open market;

o variations in interest rates;

o changes in the market valuations of other comparable
companies; and

o changes in accounting principles.

In the past, stockholders have often instituted securities class action
litigation after periods of volatility in the market price of a company's
securities. If a stockholder were to file any such class action suit against us,
we would incur substantial legal fees and our management's attention and
resources would be diverted from operating our business to respond to the
litigation, which could harm our business.

SUBSTANTIAL FUTURE SALES OF OUR COMMON STOCK IN THE PUBLIC MARKET COULD CAUSE
OUR STOCK PRICE TO FALL.

Upon the effectiveness of the Registration Statement, a significant
number of our shares of Common Stock will become eligible for sale, including
5,840,374 shares sold in the Private Placement and 767,103 shares held by
certain of our stockholders that were issued and outstanding immediately prior
to the Merger. The sale of these shares could depress the market price of our
Common Stock. A reduced market price for our shares could make it more difficult
to raise funds through future offering of Common Stock.

The holders of these shares, to the extent such shares are not
registered on the Registration Statement, as well as holders of our Common Stock
issued to holders of CNSR California Series A Preferred Stock and holders of
CNSR California Series B Preferred Stock, and certain holders of CNSR Common
Stock in the Merger, and shares of our Common Stock held by the Placement Agent
or issuable to the Placement Agent upon exercise of the Placement Agent
Warrants, shall have piggy-back registration rights with respect to such Shares
effective September 7, 2007, and demand registration rights with respect to such
Shares effective twelve (12) months following the closing of the Private
Placement.

Moreover, as additional shares of Common Stock become available for
resale in the open market (including Shares issuable upon the exercise of the
Company's outstanding options and warrants), the supply of our publicly traded
shares will increase, which could decrease its price.

Some of our shares may also be offered from time to time in the open
market pursuant to Rule 144, and these sales may have a depressive effect on the
market for our shares. In general, a person who has held restricted shares for a
period of one year may, upon filing with the Securities & Exchange Commission
(the "SEC") a notification on Form 144, sell into the market shares up to an
amount equal to 1% of the outstanding shares.

THE SALE OF SECURITIES BY US IN ANY EQUITY OR DEBT FINANCING COULD RESULT IN
DILUTION TO OUR EXISTING STOCKHOLDERS AND HAVE A MATERIAL ADVERSE EFFECT ON OUR
EARNINGS.

Any sale of Common Stock by us in a future private placement could
result in dilution to our existing stockholders as a direct result of our
issuance of additional shares of our capital stock. In addition, our business
strategy may include expansion through internal growth, by acquiring
complementary businesses, by acquiring or licensing additional products and
services, or by establishing strategic relationships with targeted customers and
suppliers. In order to do so, or to finance the cost of our other activities, we
may issue additional equity securities that could dilute our stockholders' stock
ownership. We may also assume additional debt and incur impairment losses
related to goodwill and other tangible assets if we acquire another company and
this could negatively impact our earnings and results of operations.

THE TRADING OF OUR COMMON STOCK ON THE OVER-THE-COUNTER BULLETIN BOARD AND THE
POTENTIAL DESIGNATION OF OUR COMMON STOCK AS A "PENNY STOCK" COULD IMPACT THE
TRADING MARKET FOR OUR COMMON STOCK.

Our securities, as traded on the Over-the-Counter Bulletin Board, may
be subject to SEC rules that impose special sales practice requirements on
broker-dealers who sell these securities to persons other than established
customers or accredited investors. For the purposes of the rule, the phrase
"accredited investors" means, in general terms, institutions with assets in
excess of $5,000,000, or individuals having a net worth in excess of $1,000,000
or having an annual income that exceeds $200,000 (or that, when combined with a
spouse's income, exceeds $300,000). For transactions covered by the rule, the
broker-dealer must make a special suitability determination for the purchaser
and receive the purchaser's written agreement to the transaction before the
sale. Consequently, the rule may affect the ability of broker-dealers to sell
our securities and also may affect the ability of purchasers to sell their
securities in any market that might develop therefore.

In addition, the SEC has adopted a number of rules to regulate "penny
stock" that restrict transactions involving these securities. Such rules include
Rules 3a51-1, 15g-1, 15g-2, 15g-3, 15g-4, 15g-5, 15g-6, 15g-7, and 15g-9 under
the Securities and Exchange Act of 1934, as amended. These rules may have the
effect of reducing the liquidity of penny stocks. "Penny stocks" generally are
equity securities with a price of less than $5.00 per share (other than
securities registered on certain national securities exchanges or quoted on the
NASDAQ Stock Market if current price and volume information with respect to
transactions in such securities is provided by the exchange or system). Because
our securities may constitute "penny stock" within the meaning of the rules, the
rules would apply to us and to our securities. If our securities become subject
to the penny stock rules, our stockholders may find it more difficult to sell
their securities.

Stockholders should be aware that, according to SEC, the market for
penny stocks has suffered in recent years from patterns of fraud and abuse. Such
patterns include (i) control of the market for the security by one or a few
broker-dealers that are often related to the promoter or issuer; (ii)
manipulation of prices through prearranged matching of purchases and sales and
false and misleading press releases; (iii) "boiler room" practices involving
high-pressure sales tactics and unrealistic price projections by inexperienced
sales persons; (iv) excessive and undisclosed bid-ask differentials and markups
by selling broker-dealers; and (v) the wholesale dumping of the same securities
by promoters and broker-dealers after prices have been manipulated to a desired
level, resulting in investor losses. Our management is aware of the abuses that
have occurred historically in the penny stock market. Although we do not expect
to be in a position to dictate the behavior of the market or of broker-dealers
who participate in the market, management will strive within the confines of
practical limitations to prevent the described patterns from being established
with respect to our securities.

WE HAVE NOT PAID DIVIDENDS IN THE PAST AND DO NOT EXPECT TO PAY DIVIDENDS FOR
THE FORESEEABLE FUTURE, AND ANY RETURN ON INVESTMENT MAY BE LIMITED TO POTENTIAL
FUTURE APPRECIATION ON THE VALUE OF OUR COMMON STOCK.

We currently intend to retain any future earnings to support the
development and expansion of our business and do not anticipate paying cash
dividends in the foreseeable future. Our payment of any future dividends will be
at the discretion of our Board of Directors after taking into account various
factors, including without limitation, our financial condition, operating
results, cash needs, growth plans and the terms of any credit agreements that we
may be a party to at the time. To the extent we do not pay dividends, our stock
may be less valuable because a return on investment will only occur if and to
the extent our stock price appreciates, which may never occur. In addition,
investors must rely on sales of their Common Stock after price appreciation as
the only way to realize their investment, and if the price

of our stock does not appreciate, then there will be no return on investment.
Investors seeking cash dividends should not purchase our Common Stock.

OUR OFFICERS, DIRECTORS AND PRINCIPAL STOCKHOLDERS CAN EXERT SIGNIFICANT
INFLUENCE OVER US AND MAY MAKE DECISIONS THAT ARE NOT IN THE BEST INTERESTS OF
ALL STOCKHOLDERS.

After the closing of the Merger and Private Placement, our officers,
directors and principal stockholders (greater than 5% stockholders) collectively
control approximately 33% of our issued and outstanding Common Stock. As a
result, these stockholders are able to affect the outcome of, or exert
significant influence over, all matters requiring stockholder approval,
including the election and removal of directors and any change in control. In
particular, this concentration of ownership of our Common Stock could have the
effect of delaying or preventing a change of control of us or otherwise
discouraging or preventing a potential acquirer from attempting to obtain
control of us. This, in turn, could have a negative effect on the market price
of our Common Stock. It could also prevent our stockholders from realizing a
premium over the market prices for their shares of Common Stock. Moreover, the
interests of this concentration of ownership may not always coincide with our
interests or the interests of other stockholders, and accordingly, they could
cause us to enter into transactions or agreements that we would not otherwise
consider.

TRANSACTIONS ENGAGED IN BY OUR LARGEST STOCKHOLDERS, OUR DIRECTORS OR EXECUTIVES
INVOLVING OUR COMMON STOCK MAY HAVE AN ADVERSE EFFECT ON THE PRICE OF OUR STOCK.

After the closing of the Merger and Private Placement, our officers,
directors and principal stockholders (greater than 5% stockholders) collectively
control approximately 33% of our issued and outstanding Common Stock. Subsequent
sales of our shares by these stockholders could have the effect of lowering our
stock price. The perceived risk associated with the possible sale of a large
number of shares by these stockholders, or the adoption of significant short
positions by hedge funds or other significant investors, could cause some of our
stockholders to sell their stock, thus causing the price of our stock to
decline. In addition, actual or anticipated downward pressure on our stock price
due to actual or anticipated sales of stock by our directors or officers could
cause other institutions or individuals to engage in short sales of our Common
Stock, which may further cause the price of our stock to decline.

From time to time our directors and executive officers may sell shares
of our common stock on the open market. These sales will be publicly disclosed
in filings made with the SEC. In the future, our directors and executive
officers may sell a significant number of shares for a variety of reasons
unrelated to the performance of our business. Our stockholders may perceive
these sales as a reflection on management's view of the business and result in
some stockholders selling their shares of our common stock. These sales could
cause the price of our stock to drop.

ANTI-TAKEOVER PROVISIONS MAY LIMIT THE ABILITY OF ANOTHER PARTY TO ACQUIRE US,
WHICH COULD CAUSE OUR STOCK PRICE TO DECLINE.

Delaware law contains provisions that could discourage, delay or
prevent a third party from acquiring us, even if doing so may be beneficial to
our stockholders. In addition, these provisions could limit the price investors
would be willing to pay in the future for shares of our Common Stock. See
Section captioned "DESCRIPTION OF CAPITAL STOCK - ANTI-TAKEOVER PROVISIONS."

PRINCIPAL STOCKHOLDERS PRIOR TO THE MERGER AND PRIVATE PLACEMENT

The following table sets forth certain information regarding the
Company's common stock beneficially owned prior to the Merger and Private
Placement on March 7, 2007 for (i) each shareholder we know to be the beneficial
owner of 5% or more of our outstanding common stock, (ii) each of our executive
officers and directors, and (iii) all executive officers and directors as a
group. In general, a person is deemed to be a "beneficial owner" of a security
if that person has or shares the power to vote or direct the voting of such
security, or the power to dispose or to direct the disposition of such security.
A person is also deemed to be a beneficial owner of any securities of which the
person has the right to acquire beneficial ownership within 60 days. To the best
of the Company's knowledge, all persons named have sole voting and investment
power with respect to such shares, except as otherwise noted. Immediately prior
to the Merger and Private Placement, 868,823 shares of the Company's common
stock were outstanding.
NUMBER PERCENTAGE
OF SHARES OF CLASS
BENEFICIALLY BENEFICIALLY
NAMES: OWNED OWNED
------------ ------------
NAME OF EXECUTIVE OFFICERS AND DIRECTORS

Silas Phillips, CEO, CFO, Secretary
and Sole Director ............................. 4,419 *
c/o Strativation, Inc., 10900 Wilshire Boulevard,
Suite 500, Los Angeles, California 90024

NAME OF BENEFICIAL OWNER:

Scott Absher .................................... 45,000 5.2%
18101 Von Karman Avenue, Suite 330,
Irvine, California 92612

Richardson & Patel LLP .......................... 656,103 75.5%
10900 Wilshire Boulevard, Suite 500
Los Angeles, California 90024-6525

ALL DIRECTORS AND EXECUTIVE OFFICERS
AS A GROUP (1 PERSON) ........................... 4,419 *

*Less than 1%

PRINCIPAL STOCKHOLDERS AFTER THE MERGER AND PRIVATE PLACEMENT

The following table sets forth information regarding ownership of
shares of the Company's common stock, as of March 7, 2007 taking into account
the Merger and Private Placement for (i) each shareholder we know to be the
beneficial owner of 5% or more of our outstanding common stock; (ii) each of our
executive officers and directors, and (iii) all executive officers and directors
as a group. To the best of the Company's knowledge, all persons named have sole
voting and investment power with respect to such shares, except as otherwise
noted. The table reflects a total of 24,692,190 shares outstanding as of March
7, 2007. Unless otherwise indicated, the address of each beneficial owner is c/o
CNS Response, Inc., 2755 Bristol Street, Suite 285, Costa Mesa, California
92626.

NUMBER
OF SHARES PERCENTAGE
BENEFICIALLY OF SHARES
NAME OF BENEFICIAL OWNER OWNED OUTSTANDING
- ------------------------------------------------- ------------ ------------
EXECUTIVE OFFICERS AND DIRECTORS:
Leonard Brandt (1) .............................. 8,536,277 30.4%
Director, President, Chief Executive
Officer and Secretary
David B. Jones (2) .............................. 4,338,521 16.8%
Director
Dr. Jerome Vaccaro .............................. 0 --
Director

NUMBER
OF SHARES PERCENTAGE
BENEFICIALLY OF SHARES
NAME OF BENEFICIAL OWNER OWNED OUTSTANDING
- ------------------------------------------------- ------------ ------------
Horace Hertz .................................... 0 --
Vice President Sales & Marketing
Directors and officers as a group
(4 persons) .................................. 12,874,798 44.1%

5% STOCKHOLDERS:
Stephen C. Suffin (3) ........................... 3,742,593 15.0%
Odyssey Venture Partners II, LP (2) ............. 4,338,521 16.8%
NuPharm Database, LLC (4) ....................... 3,042,513 12.3%
Brian MacDonald (5) ............................. 2,036,523 8.0%
Meyerlen, LLC (6) ............................... 1,462,205 5.8%

- ---------------------------
* Less than 1%

(1) Consists of (a) 4,347,686 shares of common stock (including 540,000
shares owned by Mr. Brandt's children), and 2,726,386 shares of common
stock issuable upon the exercise of vested and exercisable options and
warrants held by Mr. Brandt; and (b) 791,305 shares of common stock and
670,900 shares of common stock issuable upon the exercise of warrants
held by Meyerlen, LLC. Meyerlen, LLC is controlled by Mr. Brandt.

(2) Consists of (a) 3,109,406 shares of Common Stock and 1,229,115 shares
of Common Stock issuable upon the exercise of vested and exercisable
warrants held by Odyssey Venture Partners II, LP. Mr. Jones is a
partner of Odyssey Venture Partners II, LP.

(3) Consists of (a) 405,186 shares of common stock and 294,894 shares of
common stock issuable upon the exercise of vested and exercisable
options and warrants held by Mr. Suffin and (b) 3,042,513 shares of
common stock held by NuPharm Database, LLC. Mr. Suffin is the President
of NuPharm Database, LLC and exercises voting and dispositive power
over these shares.

(4) Consists of 3,042,513 shares of common stock.

(5) Consists of 1,293,859 shares of common stock and 742,664 shares of
common stock issuable upon the exercise of vested and exercisable
options to purchase common stock.

(6) Consists of 791,305 shares of common stock and 670,900 shares issuable
upon the exercise of warrants held by Meyerlen, LLC. Meyerlen, LLC is
controlled by Mr. Brandt.

DIRECTORS AND EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS

Effective as of the closing of the Merger, Silas Phillips resigned as
our prior sole officer (see ITEM 5.02 "DEPARTURE OF DIRECTORS OR PRINCIPAL
OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS") and the
following officers were appointed by the newly constituted Board of Directors:

NAME AGE POSITION
- ---------------------- --- ------------------------------------------------
Leonard J. Brandt .... 50 President, Chief Executive Officer and Secretary
Horace Hertz ......... 57 Chief Financial Officer

LEONARD J. BRANDT, DIRECTOR, PRESIDENT, CHIEF EXECUTIVE OFFICER, SECRETARY &
FOUNDER

Leonard J. Brandt is a founder of CNSR California, and has served as
its President and Chief Executive Officer, and as member of its Board of
Directors since its inception in 2000. Mr. Brandt started his career with
Norwest Venture Capital in 1980. In 1983 he became Vice President of Norwest
Growth Fund and General Partner of Norwest Venture Partners, where he served
until 1990. In this capacity he was primarily responsible for the firm's
investments in the healthcare industry, including several involving the
behavioral health industry. In 1995 Mr. Brandt founded Time Segment Publishing,
Inc and was its President until 1999. In 1999, Mr. Brandt co-founded Embro
Vascular, LLC, a provider of technology for least-invasive harvesting of the
saphenous vein for heart-bypass surgery. He also individually provided
consulting to early stage ventures from 1993 until he co-founded Mill City
Venture Consulting in 1998. Mill City Venture Consulting was initially an
advisor to NuPharm, Inc., the predecessor of CNSR California. Mr. Brandt has
been a United States member of the government of New Zealand Trade and
Enterprise Advisory Board since 2005. Len holds a Bachelor of Science degree
from the College of Commerce at University of Illinois and a Masters of Business
Administration from Harvard University.

HORACE HERTZ, CHIEF FINANCIAL OFFICER

Horace Hertz has served as Chief Financial Officer of CNSR California
since October 15, 2006. From August 2003 to September 2006, Mr. Hertz served as
the Chief Operating Officer and Chief Financial Officer of Bankers Integration
Group, a financial information company. From April 2002 to August 2003, Mr.
Hertz served as Chief Financial Officer of Infacare Pharmaceutical Corporation,
a medication development company. From April 2, 2001 to April 2002, Mr. Hertz
served as Interim Chief Executive Officer of Maxoptix, Inc., a hardware company
undergoing a restructuring. Prior to that Mr. Hertz served as a Chief Financial
Officer for a NASDAQ-listed public company, Aspeon, Inc, a manufacturer of
hardware, for 3 years. Mr. Hertz, a Certified Public Accountant, was a partner
of Deloitte & Touche, LLP from 1974 to 1991 and has a Masters Degree in
Mathematics from the University of California at Irvine.

At the closing of the Merger, the following new directors were
appointed:

NAME AGE POSITION
- ---------------------- --- ------------------------------------------------
Leonard J. Brandt .... 50 Chairman of the Board of Directors
David B. Jones ....... 63 Director
Jerome Vaccaro, M.D. . 51 Director

Please see the biography of Leonard J. Brandt set forth above.

DAVID B. JONES, DIRECTOR

David B. Jones has been a director of CNSR California since July 2006,
has been a Managing Partner of Odyssey Venture Partners II, L.P. since 2003.
From 1997 to 2003, he served as Chairman and Chief Executive Officer of Dartron,
Inc., a computer accessories manufacturer. From 1985 to 1997, he was a general
partner of InterVen Partners, a venture capital firm with offices in Southern
California and Portland, Oregon. From 1979 to 1985, he was President and Chief
Executive Officer of First Interstate Capital, Inc., the venture capital
affiliate of First Interstate Bancorp. Mr. Jones is a director of Earthanol,
Inc. He is a graduate of Dartmouth College and holds Masters of Business
Administration and law degrees from the University of Southern California.

JEROME VACCARO, M.D., DIRECTOR

Jerome Vaccaro, M.D., joined the Board of Directors of CNSR California
in 2006. Dr. Vaccaro is a Senior Vice President with United Health Group's
Specialized Care Services. He has served in a number of health care executive
roles, most recently as Chief Executive Officer of United Behavioral Health, and
before that as President and Chief Executive Officer of PacifiCare Behavioral
Health ("PBH"). Dr. Vaccaro has also served as Medical Director of PBH
(1996-2001), Chief Executive Officer of PacifiCare Dental and Vision
(2002-2004), and Senior Vice President for the PacifiCare Specialty Health
Division (2002-2004). Dr. Vaccaro has an extensive background in community
mental health and public sector work, including editing the textbook,
"Practicing Psychiatry in the Community," which is hailed as the definitive
community psychiatry text. Dr. Vaccaro completed medical school and a Psychiatry
Residency at the Albert Einstein College of Medicine in New York City. After his
training, Dr. Vaccaro served on the full-time faculty of the University of
Hawaii (1985-1989) and UCLA (1989-1996) Departments of Psychiatry.

None of the newly appointed officers or directors, nor any of their
affiliates, beneficially owned any equity securities or rights to acquire any of
our securities prior to the Merger, and no such persons have been involved in
any transaction with us or any of our directors, executive officers or
affiliates that is required to be disclosed pursuant to the rules and
regulations of the SEC, other than with respect to the transactions that have
been described herein. None of the newly appointed officers or directors has had
any bankruptcy petition filed by or against any business of which such officer
or director was a general partner or executive officer either at the time of the
bankruptcy or within two years prior to that time. None of the newly appointed
officers and directors have been convicted in a criminal proceeding, excluding
traffic violations or similar misdemeanors, nor have they been a party to any
judicial or administrative proceeding during the past five years, except for
matters that were dismissed without sanction or settlement, that resulted in a
judgment, decree or final order enjoining the person from future violations of,
or prohibiting activities subject to, federal or state securities laws, or a
finding of any violation of federal or state securities laws. There are no
family relationships among our executive officers and directors.

All members of our board of directors will serve until their terms
expire or until their successors are duly elected and qualified. Our bylaws
provide that the authorized number of directors shall be determined by
resolution of the stockholders or the board of directors, but in no event shall
be less than three (3). We intend to review and select additional candidates to
serve on our board of directors.

Currently, each of Mr. Jones and Mr. Vaccaro are considered
"independent" directors under Rule 4200(a)(15) of the National Association of
Securities Dealers listing standards. We expect to be able to

attract and recruit additional candidates to serve on our board, the timing of
which will depend on the availability and willingness of qualified independent
director candidates to serve in such capacity.

Until further determination by the Board, the full Board of Directors
will undertake the duties of the Audit Committee, Compensation Committee and
Nominating Committee of the Board of Directors.

KEY EMPLOYEES

MICHAEL TIPPIE has served as VP of Pharmaceutical Business Development for the
Company since January, 2006. Prior to CNSR, Mr. Tippie consulted for a number of
biotechnology therapeutic, diagnostic and medical device companies from January
2002 to January 2006. From 1996-2002 Mr. Tippie was VP, Business Development for
LifeSpan BioSciences, Inc., a genomic database and pathology services company,
where he was responsible for 14 transactions with large pharmaceutical
companies, as well as the management of their contract research business. Mr.
Tippie has additional senior management experience in biotechnology
(ZymoGenetics, Tacora, StressGen Biotechnologies), as well as venture capital
experience (Norwest Venture Capital under Mr. Brandt; Medical Innovation
Partners). Mr. Tippie started his career as a medicinal chemist at Syntex
Research (since acquired by Hoffman LaRoche). Mr. Tippie holds a Masters of
Business Administration from the Sloan School of Management at the Massachusetts
Institute of Technology, a Master of Science in Chemistry from the University of
Washington and a Bachelor of Science in Chemistry from Reed College.

BRIAN MACDONALD, a co-founder of the Company, has served as its Director of
Engineering since 2000. Prior to receiving his Master of Business Administration
from the Wharton School of Business, University of Pennsylvania, in 1990, Brian
was trained in operations and chemical engineering. He consulted for Deloitte &
Touche Management Consulting from July 1990 to April 1995 KPMG Strategic
Services from April 1995 through April1996 and in private practice from April
1996 until January 1999. Mr. MacDonald's focus throughout this time was in the
area of operations and information systems. Brian is co-founder of Mill City
Venture Development, an entity founded in January 1999 that consulted for the
predecessor company to CNSR. In addition to his Masters of Business
Administration, Mr. MacDonald holds a Bachelor of Science degree from the
University of Alabama.

SCIENTIFIC AND MEDIA ADVISORS

CNSR's Scientific Advisors and Media Advisors are experts in their field. During
their tenure, CNSR Board of Directors and management team utilize their
specialized expertise on an as-needed basis.

STEPHEN C. SUFFIN, MD, Advisor, is certified in anatomic and clinical pathology
and has published more than 50 scientific papers. Dr. Suffin is a former
Investigator at the Laboratory of Infectious Diseases at the National Institute
of Allergy and Infectious Diseases and consultant to the Armed Forces Institute
of Pathology before returning to the West Coast to become Medical Director at
Upjohn's Laboratory Procedures. Dr. Suffin has served as a medical director for
SmithKline Beecham and Quest Diagnostics for over 20 years. Additionally, Dr.
Suffin is a board certified psychiatrist who has served as the medical director
of two psychiatric hospitals and as the Chief Medical Officer of CNSR from its
founding in 2000 until 2002.

MAURIZIO FAVA, MD, Advisor, is currently Associate Chief of Psychiatry for
Clinical Research and Director of the Depression Clinical and Research Program
at the Massachusetts General Hospital and Professor of Psychiatry at Harvard
Medical School. Dr. Fava has authored or co-authored more than 200 original
articles, edited four books, published more than 50 chapters, 200 abstracts and
given more than 200 presentations at national or international meetings. He has
received several awards during his career and is on the editorial board of four
international medical journals. Dr. Fava's prominence in the field is

reflected by his role as the co-principal investigator of STAR*D, the largest
study ever conducted in the area of depression.

ALAN SCHATZBERG, MD, Advisor, is the Kenneth T. Norris, Jr., Professor and
Chairman of the Department of Psychiatry and Behavioral Sciences at Stanford
University. He has authored over 500 publications and abstracts, including the
MANUAL OF CLINICAL PSYCHOPHARMACOLOGY, (fifth edition published in 2005),
co-edited the TEXTBOOK OF PSYCHOPHARMACOLOGY (third edition 2003) and is
Co-Editor-in-Chief of the JOURNAL OF PSYCHIATRIC RESEARCH. He has received
numerous awards during his career, including most recently the Distinguished
Service in Psychiatry Award from the American College of Psychiatrists and is on
the editorial board of several international medical journals. In 2003, Dr.
Schatzberg was elected into the Institute of Medicine of the National Academy of
Sciences.
.
MAX A. SCHNEIDER, MD, Medical Advisor to CNSR, Director of Education, Positive
Action Center at Chapman Medical Center, Orange, California, is a Fellow and
Past President of the American Society of Addiction Medicine (ASAM), a Past
Chair of the Board of Directors of the National Council on Alcoholism and Drug
Dependence (NCADD), a former consultant to the Drug and Alcohol Advisory
Committee of the U.S. Food and Drug Administration and a Certified Medical
Review Officer. He currently serves as a Clinical Professor at the University of
California at Irvine where he teaches in their Addiction Medicine program which
he founded in 1969. Dr. Schneider has produced ten films and five booklets on
addiction. In 1956 he was a member of the research team that developed "mouth to
mouth" resuscitation that revolutionized the technique of artificial
resuscitation.

GREGORY VISTICA, Advisor to CNSR, is the president of Washington Media Group,
Inc., a communications firm that specializes in crisis management. He is also a
principal with SAIL Venture Partners, an energy/cleantech venture firm. He is an
author and former award-winning investigative journalist who has worked as a
correspondent for NEWSWEEK, a contributing writer for THE NEW YORK TIMES
MAGAZINE, a staff writer for THE WASHINGTON POST, a producer for 60 MINUTES II,
and a military affairs writer for THE SAN DIEGO UNION-TRIBUNE. He has been
nominated for an EMMY by CBS News and was a finalist for a PULITZER PRIZE
nominated by the New York Times. He won a PEABODY AWARD and THE GEORGE POLK
AWARD for his investigative reporting of the "Tailhook Scandal."

EXECUTIVE COMPENSATION

CNS RESPONSE, INC. (FORMERLY STRATIVATION, INC.)

We did not have a bonus, profit sharing, or deferred compensation plan
for the benefit of our employees, officers or directors in 2006 or 2005. We did
not pay any other salaries or other compensation above $100,000 to our officers,
directors or employees in 2006 or 2005. Further, we have not entered into an
employment agreement with any of our officers, directors or any other persons.
We have not accrued any officer compensation.

There were no option grants to any executive officers during our fiscal
year ended December 31, 2006, and no options were exercised by any executive
officer during the fiscal year ended December 31, 2006.

In 2006, none of our directors received compensation for their services
as directors on our board.

CNSR CALIFORNIA

The following table sets forth information concerning all compensation
paid to CNSR California's Executive Officers for services to CNSR California in
all capacities for each of the three fiscal years ended September 30, indicated
below.

CNS RESPONSE SUMMARY COMPENSATION TABLE

LONG-TERM
COMPENSATION
ANNUAL COMPENSATION AWARDS
------------------------------------ -----------
NUMBER OF
NAME AND FISCAL YEAR SECURITIES
PRINCIPAL ENDED OTHER ANNUAL UNDERLYING
POSITION SEPTEMBER 30, SALARY(1) BONUS COMPENSATION OPTIONS*(2)
- ------------------- ------------ --------- --------- ------------ -----------

Leonard Brandt(1) 2006 $ 175,000 $ 10,000 $ 59,700 2,124,740
Chief Executive 2005 175,000 8,000 48,900 --
Officer, Director 2004 165,000 8,000 40,400 --

* The Number of Securities Underlying Options represents the number of
shares of our Common Stock for which the CNSR California common stock
underlying the originally issued options was exchanged upon the closing
of the Merger.

(1) For the fiscal years ended 2004, 2005 and 2006 Mr. Brandt agreed to
forgo payment of his salary and allow CNSR California to accrue such
compensation. In August 2006, Mr. Brandt agreed to settle his claims
for compensation through September 30, 2006 in the aggregate amount of
$1,106,900 in exchange for the issuance of 298,437 shares of CNSR
California common stock, which were exchanged for 298,437 shares of our
Common Stock upon the closing of the Merger.

(2) The options are fully vested and exercisable at $0.132 per share.

EMPLOYMENT CONTRACTS

The Company is not currently party to any employment contracts with any
of its executive officers.

INDEMNIFICATION OF DIRECTORS AND EXECUTIVE OFFICERS AND LIMITATION OF LIABILITY

The Delaware General Corporation Law and certain provisions of our
bylaws under certain circumstances provide for indemnification of our officers,
directors and controlling persons against liabilities which they may incur in
such capacities. A summary of the circumstances in which such indemnification is
provided for is contained herein, but this description is qualified in its
entirety by reference to our bylaws and to the statutory provisions.

In general, any officer, director, employee or agent may be indemnified
against expenses, fines, settlements or judgments arising in connection with a
legal proceeding to which such person is a party, if that person's actions were
in good faith, were believed to be in our best interest, and were not unlawful.
Unless such person is successful upon the merits in such an action,
indemnification may be awarded only

after a determination by independent decision of the board of directors, by
legal counsel, or by a vote of the stockholders, that the applicable standard of
conduct was met by the person to be indemnified.

The circumstances under which indemnification is granted in connection
with an action brought on our behalf is generally the same as those set forth
above; however, with respect to such actions, indemnification is granted only
with respect to expenses actually incurred in connection with the defense or
settlement of the action. In such actions, the person to be indemnified must
have acted in good faith and in a manner believed to have been in our best
interest, and have not been adjudged liable for negligence or misconduct.

Indemnification may also be granted pursuant to the terms of agreements
which may be entered into in the future or pursuant to a vote of stockholders or
directors. The statutory provision cited above also grants the power to us to
purchase and maintain insurance which protects our officers and directors
against any liabilities incurred in connection with their service in such a
position, and such a policy may be obtained by us.

A stockholder's investment may be adversely affected to the extent we
pay the costs of settlement and damage awards against directors and officers as
required by these indemnification provisions. At present, there is no pending
litigation or proceeding involving any of our directors, officers or employees
regarding which indemnification by us is sought, nor are we aware of any
threatened litigation that may result in claims for indemnification.

Insofar as indemnification for liabilities arising under the Securities
Act may be permitted to directors, officers or persons controlling us pursuant
to the foregoing provisions, we have been informed that, in the opinion of the
SEC, this indemnification is against public policy as expressed in the
Securities Act and is therefore unenforceable.

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

CNSR CALIFORNIA

Except as follows, and as contemplated by the Merger Agreement, since
September 30, 2003, there has not been, nor is there currently proposed, any
transaction or series of similar transactions to which CNSR California is or
will be a party:

o in which the amount involved exceeds $60,000; AND

o in which any director, executive officer, other stockholders
of more than 5% of our common stock or any member of their
immediate family had or will have a direct or indirect
material interest.

From August 2000 through February 2003, Leonard J. Brandt, together
with Meyerlen, LLC, a company in which Mr. Brandt owns a controlling interest,
loaned CNSR a total of approximately $718,900 and purchased warrants to purchase
approximately 945,750 shares of CNSR California common stock, pursuant to the
terms of certain Note and Warrant Purchase Agreements. In October 2006 Mr.
Brandt agreed to cancel the promissory notes and convert the loans, including
all outstanding principal and accrued interest thereon, into 1,218,741 shares of
CNSR California's Series A-1 Preferred Stock and 255,306 shares of CNSR
California's Series A-2 Preferred Stock. At the closing of the Merger, the
1,218,741 shares of CNSR California's Series A-1 Preferred Stock and 255,306
shares of CNSR California's Series A-2 Preferred Stock converted into an
aggregate of 1,474,047 shares of our Common Stock.

In connection with the consummation of an asset purchase transaction in
January 2000, by and between Mill City/CNS, LLC and NuPharm, Mill City issued to
NuPharm Database, LLC a certain Promissory Note dated January 11, 2000 (the
"Original NuPharm Note") pursuant to which Mill City was obligated to pay
NuPharm an aggregate principal amount of $299,923.00 together with interest
pursuant to the payment schedule set forth in the Original NuPharm Note. In
January 2000, Mill City contributed substantially all of its assets, including
those securing the Original Note, to CNSR California, and CNSR California
assumed certain debts and obligations of Mill City, including Mill City's
obligations under the Original NuPharm Note. In October 2006, CNSR California
entered into an agreement with NuPharm to cancel the Original NuPharm Note in
consideration for the extension of the expiration date of a Warrant to purchase
CNSR California Common Stock held by NuPharm and a new promissory note in the
principal amount of $287,423 (the "New NuPharm Note"). Upon the closing of the
Private Placement, the principal and accrued interest through December 31, 2006
on the New NuPharm Note automatically converted into 215,567 shares of our
Common Stock.

In May 2005, April 2006 and July 2006, Odyssey Venture Partners II,
L.P. of which David Jones is a partner, loaned CNSR California an aggregate of
approximately $999,400 and purchased warrants to purchase approximately 523,305
shares of CNSR California common stock, pursuant to the terms of certain Note
and Warrant Purchase Agreements. In October 2006 Odyssey Venture Partners II,
L.P. agreed to cancel the promissory notes and convert the loans, including all
outstanding principal and accrued interest thereon, into 1,693,899 shares of
CNSR California's Series A-1 Preferred Stock and 52,907 shares of CNSR
California's Series A-2 Preferred Stock. At the closing of the Merger, the
1,693,899 shares of CNSR California's Series A-1 Preferred Stock and 255,306
shares of CNSR California's Series A-2 Preferred Stock converted into an
aggregate of 1,949,205 shares of our Common Stock.

On August 11, 2006, Mr. Brandt was granted an option to purchase
2,124,740 shares of CNSR California's common stock for an exercise price of
$0.132 per share pursuant to CNSR California's 2006 Stock Incentive Plan. At the
closing of the Merger, the option to purchase 2,124,740 shares of CNSR
California's common stock was converted into the right to purchase an aggregate
of 2,124,740 shares of our Common Stock at an exercise price of $0.132 per
share.

In September 2006, CNSR California entered into multiple settlement
agreements with its employees and consultants with respect to compensation
accrued for services provided to CNSR California. Pursuant to CNSR California's
settlement agreement with Mr. Brandt, CNSR California issued to Mr. Brandt
1,519,366 shares of its common stock in settlement of accrued compensation due
in the amount of $1,258,705.00. In connection with this settlement, CNSR
California loaned Mr. Brandt approximately $96,400 to pay the withholding tax on
the value of such shares, which loan is evidenced by a promissory note.
Immediately following the closing of the Merger, the loan to Mr. Brandt was
repaid by Mr. Brandt returning to us 78,219 shares of our common stock having a
value equal to the loan amount plus accrued interest thereon. Under a separate
Settlement Agreement, Mr. Brandt was issued 1,827,827 shares of CNSR
California's common stock in settlement of amounts owed for reimbursement for
business expenses paid by Mr. Brandt through July 2006. At the closing of the
Merger, the 1,519,366 shares of CNSR California's common stock issued pursuant
to the first of the aforementioned settlement agreements, and the 1,827,827
shares of CNSR California's common stock issued pursuant to the second of the
aforementioned settlement agreements converted into an aggregate of 3,347,193
shares of our Common Stock.

In October 2006, Odyssey Venture Partner II, L.P. invested $800,000 in
CNSR California's mezzanine financing and received 792,080 shares of CNSR
California's Series B Preferred Stock and warrants to purchase 475,248 shares of
CNSR California's common stock. David B. Jones is one of the two board members
that were designated by the holders of CNSR California's Series B Preferred
Stock pursuant to a Voting Agreement entered into in connection with the
mezzanine financing and note conversion transaction. At the closing of the
Merger, David B. Jones was appointed as a director of the company.

On March 7, 2007, Sail Venture Partners, L.P. (formerly Odyssey Venture
Partners II, L.P.) invested an aggregate of $447,000 in our Private Placement
and in exchange were issued 372,500 shares of our Common Stock and a warrant to
purchase 111,750 shares of our common stock at an exercise price of $1.80 per
share. Mr. Jones is a partner of Sail Venture Partners, L.P.

CNS RESPONSE, INC. (A DELAWARE CORPORATION)

Other than the transactions described below, since January 1, 2005,
there has not been, nor is there currently proposed, any transaction or series
of similar transactions to which we were or will be a party:

o in which the amount involved exceeds the lessor of $120,000 or
1% of the average of our total assets at year-end for the last
three completed fiscal years; and

o in which any director, executive officer, shareholder who
beneficially owns 5% or more of our common stock or any member
of their immediate family had or will have a direct or
indirect material interest.

TRANSACTIONS PRIOR TO THE MERGER

NEOTACTIX, INC. CONSULTING AGREEMENT

Prior to the Merger, on June 22, 2004, the Company and NeoTactix (NTX)
entered into a Business Consulting Agreement ("NeoTactix Agreement") pursuant to
which NeoTactix agreed to provide certain business consulting services, in
exchange for 4,500,000 shares of the Company's common stock. The Company and NTX
agreed that the compensation shares issued by the Company to affiliates of NTX
would be cancelled and returned to the Company if, prior to October 31, 2005,
the Company had not achieved certain benchmarks pursuant to the NeoTactix
Agreement. On October 5, 2005, the NeoTactix Agreement was extended to October
31, 2006. On May 31, 2006, the Board of the Company approved the waiver of the
forfeiture clause contained in the NeoTactix Agreement and it was deemed fully
performed, and then terminated.

STOCK PURCHASE AGREEMENT

Prior to the Merger, on July 18, 2006, the Company entered into a Stock
Purchase Agreement with seventeen accredited investors pursuant to which the
Company agreed to issue 3,800,000 shares of the Company's common stock to the
purchasers. The Company received an aggregate of $237,669 as consideration for
the share issuance. Mr. Silas Phillips, a former director of the company, and
the former chief executive officer, chief financial officer, and secretary of
the company was an investor in this private placement.

DEBT CANCELLATION AGREEMENTS

Prior to the Merger, on July 28, 2006, Scott Absher, our former CEO,
was paid a sum of $33,943 in full satisfaction of outstanding debt payable to
him by the Company pursuant to a Debt Cancellation Agreement. The remaining
balance of $47,612 including accrued interest was forgiven. Our former CFO,
George LeFevre, also agreed to forgive all of his outstanding debt, including
accrued interest, of $12,353 payable to the Company pursuant to a separate Debt
Cancellation Agreement.

NOTES PAYABLE

Prior to the merger, on July 28, 2006, the principal balance of the
notes payable to related parties of $28,800 were satisfied. All related interest
was forgiven by related parties.

SHARES FOR DEBT AGREEMENT

Prior to the Merger, on January 11, 2007, the Company entered into a
Shares For Debt Agreement with Richardson & Patel LLP ("R&P"), its former legal
counsel, pursuant to which the Company agreed to issue and R&P agreed to accept
645,846 restricted shares of the Company's common stock (the "Shares") as full
and complete settlement of a portion of the total outstanding debt in the amount
of $261,201.84 that the Company owed to R&P for legal services (the "Partial
Debt"). On January 15, 2007, the Company and R&P agreed to amend and restate the
Shares for Debt Agreement to increase the number of Shares to be issued in
settlement of such Partial Debt to 656,103 restricted shares of the Company's
common stock. The Amended and Restated Shares for Debt Agreement, and the terms
thereof were duly approved and ratified by the board of directors of the
Company.

REGISTRATION RIGHTS AGREEMENT

Prior to the Merger, on January 11, 2007, the Company entered into a
Registration Rights Agreement in connection with the above referenced Shares For
Debt Agreement with R&P and various other stockholders of the Corporation
signatory thereto ("Majority Stockholders") in connection with the shares of the
Company acquired pursuant to the Shares For Debt Agreement and certain other
previously disclosed or privately negotiated transactions that took place on or
around July 18, 2006. On January 15, 2007, the Company and the Majority
Stockholders agreed to amend and restate the Registration Rights Agreement to
provide registration rights to the Majority Stockholders for up to 767,103
shares of common stock of the Company held or to be acquired by them. The
Amended and Restated Registration Rights Agreement, and the terms thereof were
duly approved and ratified by the board of directors of the Company.

DESCRIPTION OF OUR CAPITAL STOCK

The information set forth below is a general summary of our capital
stock structure. As a summary, this Section is qualified by, and not a
substitute for, the provisions of our amended and restated Certificate of
Incorporation and amended and restated Bylaws.

AUTHORIZED CAPITAL STOCK

Our authorized capital stock consists of 750,000,000 shares of Common
Stock, par value $0.001 per share.

COMMON STOCK

As of March 7, 2007, we had 24,692,190 shares of Common Stock issued
and outstanding. In addition, we had reserved 10,767,028 shares of Common Stock
for issuance in respect of:

o outstanding options and warrants to purchase 8,407,517 shares
of Common Stock at exercise prices from $0.01 to $1.81 per
share; and

o outstanding warrants to purchase 2,359,511 shares of Common
Stock at exercise prices from $1.44 to $1.80 per share.

DIVIDEND RIGHTS

The holders of outstanding shares of Common Stock are entitled to
receive dividends out of funds legally available at the times and in the amounts
that our Board may determine.

VOTING RIGHTS

Each holder of Common Stock is entitled to one vote for each share of
Common Stock held on all matters submitted to a vote of stockholders.

NO PREEMPTIVE OR SIMILAR RIGHTS

Holders of Common Stock do not have preemptive rights, and Common Stock
is not convertible or redeemable.

RIGHT TO RECEIVE LIQUIDATION DISTRIBUTIONS

Upon our dissolution, liquidation or winding-up, the assets legally
available for distribution to our stockholders are distributable ratably among
the holders of Common Stock.

ANTI-TAKEOVER PROVISIONS

Delaware has enacted the following legislation that may deter or
frustrate takeovers of Delaware corporations, such as CNS Response:

SECTION 203 OF THE DELAWARE GENERAL CORPORATION LAW. Section 203
provides, with some exceptions, that a Delaware corporation may not engage in
any of a broad range of business combinations with a person or affiliate, or
associate of the person, who is an "interested stockholder" for a period of
three years from the date that the person became an interested stockholder
unless: (i) the transaction resulting in a person becoming an interested
stockholder, or the business combination, is approved by the board of directors
of the corporation before the person becomes an interested stockholder; (ii) the
interested stockholder acquires 85% or more of the outstanding voting stock of
the corporation in the same transaction that makes it an interested stockholder,
excluding shares owned by persons who are both officers and directors of the
corporation, and shares held by some employee stock ownership plans; or (iii) on
or after the date the person becomes an interested stockholder, the business
combination is approved by the corporation's board of directors and by the
holders of at least 66 2/3% of the corporation's outstanding voting stock at an
annual or special meeting, excluding shares owned by the interested stockholder.
An "interested stockholder" is defined as any person that is (a) the owner of
15% or more of the outstanding voting stock of the corporation or (b) an
affiliate or associate of the corporation and was the owner of 15% or more of
the outstanding voting stock of the corporation at any time within the
three-year period immediately prior to the date on which it is sought to be
determined whether the person is an interested stockholder.

AUTHORIZED BUT UNISSUED STOCK. The authorized but unissued shares of
our common stock are available for future issuance without shareholder approval.
These additional shares may be used for a variety of corporate purposes,
including future public offering to raise additional capital, corporate
acquisitions and employee benefit plans. The existence of authorized but
unissued shares of common stock may enable our Board to issue shares of stock to
persons friendly to existing management.

TRANSFER AGENT AND REGISTRAR

The transfer agent and registrar for our common stock is Fidelity Stock
Transfer. The address of Fidelity Transfer Company is 1800 South West Temple,
Ste. 301, Salt Lake City, UT 84115, and the phone number is (810) 484-7222.

LISTING

Our common stock is currently quoted on the Over-The-Counter Bulletin
Board under the trading symbol "CNSO.OB".

MARKET PRICE OF AND DIVIDENDS ON THE REGISTRANT'S COMMON EQUITY AND RELATED
STOCKHOLDER MATTERS.

Our common stock is currently listed for trading on the OTCBB under the
symbol CNSO.OB. The following table sets forth, for the periods indicated, the
high and low bid information for Common Stock as determined from sporadic
quotations on the OTC Bulletin Board. The following quotations reflect
inter-dealer prices, without retail mark-up, mark-down or commission and may not
represent actual transactions.

HIGH LOW
--------------- ---------------
FISCAL YEAR ENDED DECEMBER 31, 2006
First Quarter ..................... $0.07 ($3.50*) $0.06 ($3.00*)
Second Quarter .................... $0.08 ($4.00*) $0.06 ($3.00*)
Third Quarter ..................... $0.17 ($8.50*) $0.07 ($3.50)
Fourth Quarter .................... $0.17 ($8.50*) $0.01 (0.50*)

HIGH LOW
--------------- ---------------
FISCAL YEAR ENDED DECEMBER 31, 2005
First Quarter ..................... $0.10 ($5.00*) $0.045 ($2.25*)
Second Quarter .................... $0.10 ($5.00*) $0.035 ($1.75*)
Third Quarter ..................... $0.065 ($3.25*) $0.03 ($1.50*)
Fourth Quarter .................... $0.09 ($4.50*) $0.036 (1.80*)

* Adjusted price reflecting the 1:50 reverse stock split that became
effective January 10, 2007

On March 7, 2007, the closing sales price of Common Stock as reported
on the OTC Bulletin Board was $2.00 per share. As of March 7, 2007, there were
approximately 264 holders of record of our Common Stock.

DIVIDENDS. We have never paid dividends on our common stock. CNSR
California has never paid dividends on its common stock. We presently intend to
retain any earnings for use in our business.

SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS.

The following table sets forth information concerning our equity
compensation plans as of September 30, 2006.

NUMBER OF SECURITIES NUMBER OF SECURITIES REMAINING
TO BE ISSUED UPON WEIGHTED-AVERAGE AVAILABLE FOR FUTURE ISSUANCE
EXERCISE OF EXERCISE PRICE OF UNDER EQUITY COMPENSATION
OUTSTANDING OPTIONS, OUTSTANDING OPTIONS, PLANS (EXCLUDING SECURITIES
WARRANTS AND RIGHTS WARRANTS AND RIGHTS REFLECTED IN COLUMN (A))
PLAN CATEGORY (a) (b) (c)
- --------------------------------- -------------------- -------------------- ------------------------------

Equity compensation plans ....... 4,000,403 $0.13 5,815,660
approved by security holders
Equity compensation plans not ... -- -- --
approved by security holders

TOTAL ........................... 4,000,403 $0.13 5,815,660

RECENT SALES OF UNREGISTERED SECURITIES BY CNSR CALIFORNIA

PREFERRED STOCK TRANSACTIONS

NOTE CONVERSION TRANSACTION

MEZZANINE FINANCING

COMMON STOCK TRANSACTIONS

SETTLEMENT AGREEMENT FINANCING

CONVERSION OF NUPHARM DATABASE, LLC PROMISSORY NOTE

In connection with the consummation of an asset purchase transaction in
January 2000, by and between Mill City/CNS, LLC and NuPharm, Mill City issued to
NuPharm Database, LLC a certain

Promissory Note dated January 11, 2000 (the "Original NuPharm Note") pursuant to
which Mill City was obligated to pay NuPharm an aggregate principal amount of
$299,923.00 together with interest pursuant to the payment schedule set forth in
the Original NuPharm Note. In January 2000, Mill City contributed substantially
all of its assets, including those securing the Original Note, to CNSR
California, and CNSR California assumed certain debts and obligations of Mill
City, including Mill City's obligations under the Original NuPharm Note.

Please also see the disclosure set forth above in relation to the
shares of common stock that were issued in the Merger and Private Placement.

STOCK OPTIONS

OPTION GRANT TO LEONARD BRANDT

On August 11, 2006, Mr. Brandt was granted an option to purchase
2,124,740 shares of CNSR California's common stock for an exercise price of
$0.132 per share pursuant to CNSR California's 2006 Stock Incentive Plan. At the
closing of the Merger, the option to purchase 2,124,740 shares of CNSR
California's common stock was converted into the right to purchase an aggregate
of 2,142,740 shares of our Common Stock at an exercise price of $0.132 per
share.

In connection with the above stock issuances and option grants, CNSR
California did not pay any underwriting discounts or commissions. None of the
sales of securities described or referred to above was registered under the
Securities Act of 1933, as amended (the "Securities Act"). Each of the
purchasers fell into one or more of the categories that follow: one of the
Company's existing stockholders, one of the company's creditors, one of the
company's current or former officers or directors, one of the company's service
providers, or an accredited investor with whom the company or one of its
affiliates had a prior business relationship. As a result, no general
solicitation or advertising was used in connection with the sales. In making the
sales without registration under the Securities Act, the company relied upon one
or more of the exemptions from registration contained in Sections 4(2) of the
Securities Act, and in Regulation D promulgated under the Securities Act.

RECENT SALES OF UNREGISTERED SECURITIES BY CNSR DELAWARE

Reference is made to the Stock Purchase Agreement entered into on July
18, 2006, and the Shares for Debt Agreement entered into on January 11, 2007
described above in the section entitled Certain Relationships and Related
Transaction, which is hereby incorporated by reference.

In connection with the above stock issuances and option grants, CNSR
Delaware did not pay any underwriting discounts or commissions. None of the
sales of securities described or referred to above was registered under the
Securities Act. Each of the purchasers fell into one or more of the categories
that follow: one of the Company's existing stockholders, one of the company's
creditors, one of the company's current or former officers or directors, one of
the company's service providers, or an accredited investor with whom the company
or one of its affiliates had a prior business relationship. As a result, no
general solicitation or advertising was used in connection with the sales. In
making the sales without registration under the Securities Act, the company
relied upon one or more of the exemptions from registration contained in
Sections 4(2) of the Securities Act, and in Regulation D promulgated under the
Securities Act.

ITEM 3.02 UNREGISTERED SALES OF EQUITY SECURITIES

Reference is made to the disclosure set forth under Item 2.01 of this
Current Report on Form 8-K, which disclosure is incorporated herein by
reference.

ITEM 4.01 CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT.

(a) Simultaneously with the closing of the Merger, we dismissed
Spector & Wong, LLP ("Spector & Wong") as our independent certified public
accountants. The decision was approved by our Board of Directors. The report of
Spector & Wong on our financial statements for the fiscal years ended December
31, 2006 and 2005 did not contain an adverse opinion or disclaimer of opinion
and were not modified as to uncertainty, audit scope, or accounting principles,
except the 2006 report did contain an explanatory paragraph related to our
ability to continue as a going concern. During our fiscal years ended December
31, 2006 and 2005, and through March 7, 2007 (the effective date of Spector &
Wong's dismissal), there were no disagreements with Spector & Wong on any matter
of accounting principles or practices, financial statement disclosure, or
auditing scope or procedure, which disagreements, if not resolved to the
satisfaction of Spector & Wong would have caused Spector & Wong to make
reference to the subject matter of the disagreements in connection with its
reports. We furnished Spector & Wong with a copy of this Report on Form 8-K
prior to filing with the SEC. We also requested that Spector & Wong furnish us
with a letter addressed to the Securities and Exchange Commission ("SEC")
stating whether or not it agrees with our statements in this Report. A copy of
the letter furnished by Spector & Wong in response to that request, dated March
7, 2007, is filed as Exhibit 16.1 to this Form 8-K.

(b) On March 7, 2007, upon the closing of the Merger, our Board of
Directors approved the appointment of Cacciamatta Accountancy Corporation, LLP
("Cacciamatta"), as our new registered public accounting firm. During our two
most recent fiscal years and through the date of this Report on

Form 8-K, we did not consult with Cacciamatta with respect to the application of
accounting principles to a specified transaction, either completed or proposed,
or the type of audit opinion that might be rendered on our financial statements,
or any other matters or reportable events listed in Item 304(a)(2)(i) or (ii) of
Regulation S-B.

ITEM 5.01 CHANGES IN CONTROL OF REGISTRANT.

Reference is made to the disclosure set forth under Item 2.01 of this
Current Report on Form 8-K, which disclosure is incorporated herein by
reference.

ITEM 5.02 DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS;
APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN
OFFICERS.

Reference is made to the disclosure set forth under Item 2.01 of this
Current Report on Form 8-K, which disclosure is incorporated herein by
reference.

ITEM 5.03 AMENDMENTS TO ARTICLES OF INCORPORATION OR BYLAWS; CHANGE IN FISCAL
YEAR

Reference is made to the disclosure set forth under Item 2.01 of this
Current Report on Form 8-K, with respect to our name change from Strativation,
Inc. to CNS Response, Inc., which disclosure is incorporated herein by
reference.

In connection with the Merger, our Board of Directors approved a change
in fiscal year end from December 31 to September 30. We will account for the
Merger as a "reverse acquisition." Consequently, we will not file a transition
report reflecting the change of our fiscal year to that of CNSR California,
given the fact that for accounting purposes, CNSR California is deemed to be the
"accounting acquirer" in the "reverse acquisition."

ITEM 5.06 CHANGE IN SHELL COMPANY STATUS

Reference is made to the disclosure set forth under Item 2.01 and 5.01
of this Current Report on Form 8-K, which disclosure is incorporated herein by
reference.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(a) FINANCIAL STATEMENTS OF BUSINESSES ACQUIRED

The audited financial statements of CNSR California for the fiscal
years ended September 30, 2006 and 2005 are incorporated herein by reference to
Exhibit 99.2 to this Current Report. The unaudited financial statements of CNSR
California for the quarterly period ended December 31, 2006 and 2005 are
incorporated herein by reference to Exhibit 99.2 to this Current Report.

(b) PRO FORMA FINANCIAL STATEMENTS

We acquired CNSR California in a reverse merger transaction in which
all of the issued and outstanding securities of CNSR California were converted
into our securities. Immediately prior to the reverse merger on March 7, 2007,
we had no operations, no assets, and no liabilities. Accordingly, for all

meaningful purposes the Audited Financial Statements for CNSR California which
are filed with this Current Report on Form 8-K comprise our pro forma financials
as well. Preparation of independent, unaudited pro forma financials other than
the Financial Statements filed herewith would have imposed a substantial burden
upon us as the surviving entity at this time without any meaningful additional
disclosure.

Reference is made to the disclosure set forth under Item 9.01(a) and
9.01(b) of this Current Report on Form 8-K, which disclosure is incorporated
herein by reference.

(d) EXHIBITS

See attached Exhibit Index.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

CNS Response, Inc.

Date: March 13, 2007 By: /s/ Leonard J. Brandt
-------------------------------------
Leonard J. Brandt
President and Chief Executive Officer

EXHIBIT INDEX

EXHIBIT NUMBER DESCRIPTION OF EXHIBITS
- -------------- --------------------------------------------------------------
2.1 Agreement and Plan of Merger between Strativation, Inc., CNS
Merger Corporation and CNS Response, Inc. dated as of January
16, 2007, incorporated by reference to Exhibit No. 10.1 to the
Registrant's Current Report on Form 8-K (File No. 000-26285)
filed with the Commission on January 22, 2007.
- -------------- --------------------------------------------------------------
2.2 Amendment No. 1 to Agreement and Plan of Merger by and among
Strativation, Inc., CNS Merger Corporation, and CNS Response,
Inc. dated as of February 28, 2007, incorporated by reference
to Exhibit No. 10.1 to the Registrant's Current Report on Form
8-K (File No. 000-26285) filed with the Commission on March 1,
2007.
- -------------- --------------------------------------------------------------
3.1.1 Certificate of Incorporation, dated March 17, 1987,
incorporated by reference to Exhibit No. 3(i) to the
Registrant's Form 10-SB (File No. 000-26285) filed with the
Commission on June 7, 1999.
- -------------- --------------------------------------------------------------
3.1.2 Certificate of Amendment of Certificate of Incorporation,
dated June 1, 2004, incorporated by reference to Exhibit 16 to
the Registrant's Current Report on Form 8-K (File No.
000-26285) filed with the Commission on June 8, 2004.
- -------------- --------------------------------------------------------------
3.1.3 Certificate of Amendment of Certificate of Incorporation,
dated August 2, 2004, incorporated by reference to Exhibit 16
to the Registrant's Current Report on Form 8-K (File No.
000-26285) filed with the Commission on August 5, 2004.
- -------------- --------------------------------------------------------------
3.1.4 Certificate of Ownership and Merger Merging CNS Response,
Inc., a Delaware corporation, with and into Strativation,
Inc., a Delaware corporation, dated March 7, 2007.
- -------------- --------------------------------------------------------------
3.2 Bylaws, incorporated by reference to Exhibit No. 3(ii) to the
Registrant's Form 10-SB (File No. 000-26285) filed with the
Commission on June 7, 1999.
- -------------- --------------------------------------------------------------
4.1 Form of Warrant issued to Investors in Private Placement.
- -------------- --------------------------------------------------------------
10.1 Stock Purchase Agreement by and among the Registrant and
George LeFevre, Scott Absher, and the purchasers signatory
thereto dated July 18, 2006 Incorporated by reference from the
Registrant's Current Report on Form 8-K (File No. 000-26285)
filed with the Commission on July 24, 2006.
- -------------- --------------------------------------------------------------
10.2 Amended and Restated Shares for Debt Agreement, dated January
16, 2007 by and between the Registrant and Richardson & Patel
LLP 2007, incorporated by reference to Exhibit No. 10.1 to the
Registrant's Current Report on Form 8-K (File No. 000-26285)
filed with the Commission on January 16, 2007.
- -------------- --------------------------------------------------------------
10.3 Amended and Restated Registration Rights Agreement, dated
January 16, 2007 by and among the Registrant and the
stockholders signatory thereto, incorporated by reference to
Exhibit No. 10.2 to the Registrant's Current Report on Form
8-K (File No. 000-26285) filed with the Commission on January
16, 2007.
- -------------- --------------------------------------------------------------
10.4 Form of Subscription Agreement between the Registrant and
certain investors, dated March 7, 2007.
- -------------- --------------------------------------------------------------
10.5 Form of Indemnification Agreement by and among the Registrant,
CNS Response, Inc., a California corporation, and certain
individuals, dated March 7, 2007.
- -------------- --------------------------------------------------------------
10.6 Form of Registration Rights Agreement by and among the
Registrant and certain Investors signatory thereto dated March
7, 2007.
- -------------- --------------------------------------------------------------
10.7 Form of Registration Rights Agreement by and among the
Registrant and certain stockholders of the Company signatory
thereto dated March 7, 2007.
- -------------- --------------------------------------------------------------
16.1 Letter from Spector & Wong, LLP.
- -------------- --------------------------------------------------------------
21 Subsidiaries of the Registrant.
- -------------- --------------------------------------------------------------
99.1 Press Release issued by CNS Response, Inc. dated March 9,
2007.
- -------------- --------------------------------------------------------------
99.2 Financial statements of CNS Response, Inc. for the fiscal
years ended September 30, 2006 and 2005, and unaudited
financial statements for the three-month periods ended
December 31, 2006 and 2005.
- -------------- --------------------------------------------------------------